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EXAMINATION OF RACIAL/ETHNIC DISPARITIES IN OVARIAN CANCER STAGE OF
DIAGNOSIS, SURGERY TREATMENT AND SURVIVAL: MULTILEVEL ANALYSIS OF
2001—2012 SEER DATA
by
CHEN CHEN
(Under the Direction of Yelena N. Tarasenko)
ABSTRACT
Context. Racial/ethnic disparities in cancer outcomes are major public health concerns.
Ovarian cancer is the tenth most common cancer and the fifth leading cause of cancer-related
deaths among women. Identifying individual- and contextual-level factors contributing to
racial/ethnic disparities in ovarian cancer stage of diagnosis, surgery treatment, and survival is
necessary for reducing and eliminating these disparities.
Objective. The study aims to examine racial/ethnic disparities in ovarian cancer diagnosis,
surgery treatment and survival outcomes; to explore individual- and contextual-level factors
contributing to these disparities, and to examine the trend of ovarian cancer racial/ethnic disparities
from 2001 to 2012.
Methods. The study was based on the Surveillance, Epidemiology, and End Results data.
Multilevel binary logistic regressions were used for the analysis of racial/ethnic disparities in late
stage diagnosis and receipt of surgery adjusted for both individual- and county-level factors,
respectively. Multilevel Cox-proportional hazards models were applied to analyze the racial/ethnic
disparities in ovarian cancer-cause specific mortality. Joinpoint regression models were used to
analyze the trend of ovarian cancer racial/ethnic disparities over time.
Result. Adjusting for age at diagnosis, marital status, tumor pathological characteristics,
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metro/nonmetro residence, and indicators of socioeconomic status of county residents, compared
to Non-Hispanic white (NHW) patients, non-Hispanic black (NHB) patients have significantly
higher probability of advanced stage diagnosis (75.44% vs. 69.52%; p=0.001), but this difference
is only significant for patients living in counties with the employment rate ranked in the highest
quartile. NHW patients have the highest adjusted probability of receiving surgery treatment
(83.40%, 95%CI: 83.04% - 83.76%), whereas Hispanic patients (81.96%, 95%CI: 81.16% 82.76%) and NHB patients (77.65%, 95%CI: 76.73% - 78.58%) have the lowest adjusted
probability (p <0.05). Compared to NHW patients, NHB patients have 24% increased hazards of
ovarian cancer death (95% CI: 1.18 – 1.30, p<0.001). Both individual- and contextual-level factors
contribute to racial/ethnic disparities in ovarian cancer. From 2001-2012, the extent of racial/ethnic
disparities in ovarian cancer remained stable (p’s<0.05).
Conclusion. The associations between individual- and contextual-level factors and
ovarian cancer outcomes vary by race/ethnicity and should be examined separately. Multilevel
culturally tailored efforts are required to decrease racial/ethnic disparities in ovarian cancer.
INDEX WORDS: Ovarian cancer, Diagnosis, Surgery, Survival, Racial/ethnic disparities, multilevel, SEER
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CHAPTER 1
BACKGROUND
Being the deadliest of gynecologic cancers, ovarian cancer is the eleventh most common
cancer and the fifth leading cause of cancer-related deaths among women (Ovarian Cancer
National Alliance, 2014a). According to the Surveillance, Epidemiology, and End Results (SEER)
statistics, based on 2008-2012 cancer cases and deaths, the number of new cases of ovarian cancer
was 12.1 per 100,000 women per year, and the number of deaths was 7.7 per 100,000 women per
year (National Cancer Institute, 2015a). In 2011, there were approximately 188,867 women alive
who had a history of ovarian cancer (National Cancer Institute, 2015a). It is estimated that, in 2015,
21,290 women (i.e. 1.3% of all new cancer cases) will be diagnosed with and 14,180 women (i.e.
2.4% of all cancer deaths) will die of ovarian cancer (National Cancer Institute, 2015a).
Ovarian cancer is often diagnosed at a later stage due to vaguely presented symptoms and
lack of reliable screening tests for general female population. Certain tests are available for
assisting with diagnosis of women with high risk; however, the only way for definitive diagnose
is through surgery and biopsy. Upon diagnosis, the treatment plan usually depends on the cancer
stage and histology type. Surgery, chemotherapy and radiotherapy are the main treatments for
ovarian cancer.
Several genetic risk factors are associated with the development of ovarian cancer. For
example, women with a family history of ovarian cancer are at increased risk (US Preventive
Services Task Force [USPSTF], 2014a). Mutations in BRCA1 and BRCA2 genes are responsible
for most inherited ovarian cancers, and the mutations in those two genes are also linked with high
risk of inherited breast cancer (American Cancer Society, 2014c; Holschneider & Berek, 2000).
Behavioral factors also contribute to the development of ovarian cancer. For example,
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being obese and use of postmenopausal estrogen are associated with increased ovarian cancer risk
(American Cancer Society, 2014c; National Cancer Institute, 2014). Because the development of
ovarian cancer is associated with the number of lifetime ovulations, factors that reduce ovulation,
such as pregnancy, breast feeding, and use of oral contraceptive pills, and previous hysterectomy
or sterilization are associated with reduced ovarian cancer risk (Edmondson & Todd, 2008;
Holschneider & Berek, 2000; National Cancer Institute, 2014).
In addition to the genetic and behavioral risk factors, socioeconomic environment is an
important factor which may influence ovarian cancer diagnosis, treatment and prognosis through
differences in healthcare accessibility. Research has demonstrated a strong relationship between
socioeconomic environment and healthcare accessibility (Breen & Figueroa, 1996; Coughlin,
Leadbetter, Richards, & Sabatino, 2008; Kirby & Kaneda, 2005, 2006; Litaker, Koroukian, & Love,
2005; Prentice, 2006). Management of ovarian cancer and related complications requires a longterm and systematic approach. Living in a community with majority of residents characterized by
low socio-economic status (SES) or rural communities where the allocation of medical resources
is limited, may constrict people’s individual accessibility for healthcare services (Hendryx, Ahern,
Lovrich & McCurdy, 2002; Kirby & Kaneda, 2005).
SES has long been linked with race/ethnicity. There is also a significant interaction effect of
race and SES on health outcomes. For example, based on the US National Health and Nutrition
Examination Survey, Farmer and Ferraro found that the racial disparity between white and black
adults in self-rated health was largest at the higher levels of SES. The finding may indicate that
improvements in SES does not necessarily translate into improvements in health outcomes of
people from different racial groups (Farmer & Ferraro, 2005). Despite improvements in cancer
care during the past two decades, racial/ethnic disparities in ovarian cancer still exist in the United
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States. According to the Centers for Disease Control and Prevention (CDC) 2011 statistics, white
women had the highest incidence rate of ovarian cancer, followed by Hispanic, Asian/Pacific
Islander, Black, and American Indian/Alaska Native women. White women also had the highest
death rate of ovarian cancer, followed by Black, Hispanic, Asian/Pacific Islander, and American
Indian/Alaska Native women (Centers for Disease Control and Prevention [CDC], 2014). Racial
disparities in ovarian cancer have been documented with respect to stage of diagnosis, treatment,
and survival outcomes (Farley, Risinger, Rose, & Maxwell, 2007; Tammemagi, 2007; Terplan,
Schluterman, McNamara, Tracy, & Temkin, 2012). However, the extent to which these disparities
reflect unequal access to health care and whether the disparities can be explained by individuallevel, contextual-level characteristics or a combination thereof remains unclear.
Further research is needed to identify contextual-level factors associated with racial/ethnic
disparities in ovarian cancer outcomes. Lack of such knowledge is an important barrier to
decreasing the health disparities in the United States. For other cancer diseases, contextual level
SES has been found to be associated with disparities in cancer outcomes (Ward et al., 2004; Breen
& Figueroa, 1996; Coughlin, et al., 2008; Robert et al., 2004). However the contribution of
socioeconomic characteristics of community in ovarian cancer outcomes is not understood.
Variations in US ovarian cancer outcomes by rurality is also unknown, especially based on
national level data. With the rapid urbanization, urban environments are more likely to see large
disparities in socioeconomic status (Unite For Sight, 2014). Also, with the growth of minority
population in rural areas, part of the health disparities may also be attributed to lifestyle differences
(Unite For Sight, 2014). As a result, although generally speaking, people living in rural areas are
more likely to be of lower SES than their urban counterparts, the health disparity by rural/urban
residence may not be fully explained by SES differences. Rural counties can have communities
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with high SES, and rural/urban difference in health outcomes may also be attributed to factors such
as differences in life styles and living environment. Examining rural/urban differences in health
outcomes can provide insights on the development of policies to targeting rural areas.
The effects of socioeconomic environment, rural/urban residence, and individual-level
factors on development and prognosis of ovarian cancer disease are unknown. Study based on
examination of individual-level factors have limited health policy and intervention development
implications. Failure to consider potential interaction effects between multilevel factors may lead
to unwise recommendation for policy development (e.g. inefficient allocation of medical resources)
which may slow down the progress of health promotion. This study relies on constructs of a social
ecological model which integrates multilevel factors and provides conceptual framework for
studying the interaction effects of those factors on ovarian cancer health outcomes (Glanz, Rimer,
& Viswanath, 2008). The main hypotheses of the study are (i) there are racial/ethnic disparities in
ovarian cancer stage of diagnosis, receipt of surgery treatment and survival outcome, and (ii) both
individual-level characteristics (such as age, marital status, and pathological characteristics) and
contextual-level factors (such as county-level SES and metro/nonmetro residence) contribute to
these racial/ethnic disparities.
The study aims to examine racial/ethnic disparities in ovarian cancer diagnosis, surgery
treatment and survival outcomes; explore individual- and contextual-level factors contributing to
these disparities and examine trend in ovarian cancer racial/ethnic disparities from 2001 to 2012.
The study findings are expected to provide insights into mechanisms through which ovarian cancer
racial/ethnic disparities are developed; inform policy-makers about the subpopulation which
suffers an excessive ovarian cancer burden, and update knowledge on the trend of ovarian cancer
racial/ethnic disparities based on a national level cancer registry data.
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CHAPTER 2
LITERATURE REVIEW
Ovarian Cancer: Symptoms, Diagnosis and Treatment
The development of ovarian cancer can be accompanied by several symptoms. Some of the
potential symptoms include pelvic mass, such as urinary frequency, pain, and constipation. There
are also symptoms related to other intra-abdominal disease, including disease of or invading the
bowel, such as rectal bleeding or altered bowel habit; or the presence of ascites, leading to
abdominal dissension; or some other general symptoms related to cancer, such as nausea, vomiting,
anorexia, and cachexia (Edmondson & Todd, 2008). However, because the symptoms often are
not acute or intense and present vaguely, particularly in the early stages, most women are not
diagnosed until the disease had been progressed to the advanced stage (National Ovarian Cancer
Coalition, 2014a).
When ovarian cancer is found early at a localized stage, about 94% of patients live longer than
5 years after diagnosis (American Cancer Society, 2014a). For women with high risks, such as
those showing ovarian cancer symptoms, a strong family history, or a genetic predisposition,
several screening tests are performed to help with diagnosis, including a complete pelvic exam, a
transvaginal or pelvic ultrasound, or a CA-125 blood test (Ovarian Cancer National Alliance,
2014b). However, screening tests for ovarian cancer are not recommended for general
asymptomatic women by major medical and public health organizations including the U. S.
Preventive Services Task Force (USPSTF), the American Congress of Obstetricians and
Gynecologists, and the American Cancer Society (American Cancer Society, 2014a; Committee
Opinion No. 477: The Role of The Obstetrician-Gynecologist in The Early Detection of Epithelial
Ovarian Cancer, 2011; USPSTF, 2014a). The positive predictive value (PPV) of screening for

14

ovarian cancer is low due to the low prevalence of the diseases (with an age-adjusted incidence of
13 cases per 100,000 women), as a result, most women with a positive screening test result are
false-positive (USPSTF, 2014a). According to the Health Technology Assessment’s review of 16
cohort studies on ovarian cancer screening among asymptomatic, average-risk women, using
annual ultrasound screening, only 0.6 percent of those recalled for abnormal results, and 3 percent
underwent surgery, have cancer. The PPV for CA 125-based multimodal screening (CA 125
followed by ultrasound if CA 125 levels are high) was estimated as 1 percent for initial recall and
15 percent for surgery. An estimated 3 percent to 12 percent of screened women will be recalled
for further testing and assessment, resulting in potential distress and anxiety to otherwise healthy
women. Approximately 0.5 percent to 1 percent of women will suffer a significant complication
because of surgery (USPSTF, 2014b). Besides the potential harms of unnecessary surgery or
repeated testing, based on a randomized controlled trial of 78,216 women in the U.S. population,
simultaneous screening with CA-125 and transvaginal ultrasound does not reduce ovarian cancer
mortality (Buys, Partridge, Black, & et al., 2011).
Although the aforementioned tests can improve ovarian cancer diagnosis among women with
symptoms or high risks, when used individually, these tests are not definitive. Currently, the only
definitive way for ovarian diagnose is through surgery and biopsy (Ovarian Cancer National
Alliance, 2014b).
Once diagnosed with ovarian cancer, the stage of a tumor can be determined during surgery.
Depending on whether the cancer spreads outside the ovaries, ovarian cancer can be classified into
four stages: from Stage I (early disease) to Stage IV (advance disease) (National Ovarian Cancer
Coalition, 2014c). According to the type of cell from which the cancer starts, ovarian cancer is
classified into three types: (1) surface Epithelium-cells covering the lining of the ovaries, (2) germ
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cell-cells destined to form eggs, and (3) stromal cells releasing hormones and connecting the
different structures of the ovaries (National Ovarian Cancer Coalition, 2014c). Epithelial ovarian
tumor, which accounts for 90% of the ovarian neoplasms and 70% of all ovarian malignancies is
further classified as serous (30-70%), endometrioid (10-20%), mucinous (5-20%), clear cell (310%), and undifferentiated (1%) (Rosen et al., 2009).
Treatment plan usually depends on the kind of ovarian cancer and how far it has spread (CDC,
2014c). Currently, there are three types of ovarian cancer treatment: (1) surgery to remove the
cancerous growth; (2) chemotherapy to deliver chemicals through the bloodstream to destroy
cancer cells or stop them from growing both in and outside the ovaries, and (3) radiation therapy
to use high-energy X-rays to kill cancer cells and shrink tumors. Chemotherapy is used in the
majority of cases as a follow-up therapy to surgery, and radiation therapy is only rarely used in the
treatment of ovarian cancer in the United States (National Ovarian Cancer Coalition, 2014b).

Factor Influencing Ovarian Cancer Diagnosis, Treatment and Survival
Literature suggests that multilevel factors can influence ovarian cancer diagnosis, treatment
and survival outcomes.
Individual-level Factors:
Pathological Factors
Ovarian cancer stage at diagnosis, histology type, and grade of disease have been found to be
important prognostic factors for survival (Chan, et al., 2008; Holschneider & Berek, 2000;
Tingulstad, Skjeldestad, Halvorsen, & Hagen, 2003). Based on the statistics from the National
Cancer Institute, SEER Data 2004-2010, the relative 5-year survival rates by ovarian cancer stage
are as follows: 90% for stage I, 70% for stage II, 39% for stage III, and 17% for stage IV (American
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Cancer Society, 2014b). Based on a systematic review of ovarian cancer pathology and biology,
the survival outcome also vary by ovarian cancer histology type. The 5-year survival rates are 2035% for serous type, 40-63% for endometrioid type, 40-69% for mucinous type, 35-50% for clear
cell type, and 11-29% for undifferentiated type (Rosen, et al., 2009). Furthermore, the treatment
plan also greatly depends on cancer pathology (National Ovarian Cancer Coalition, 2014b). Hence,
pathological factors need to be controlled for in modeling ovarian cancer disparities.
Race/Ethnicity:
Race/ethnicity is an important contributor to health disparities. A broad range of factors such
as social, behavioral, nutritional, psychological, residential, occupational can lead to racial and
ethnic disparities in health.

The interaction between biological factors and social/natural

environmental factors could be complex. The reasons for racial disparities in health outcomes are
multifactorial. Emerging studies suggest that the effects of unequal access to treatment have
amplified racial disparities in survival from ovarian cancer (Chan et al., 2008; Terplan, et al., 2012;
Terplan, Smith, & Temkin, 2009).
Previous studies yield inconsistent results on racial/ethnic disparities in ovarian cancer
diagnosis. For instance, a study based on 1995-2007 SEER Medicare-linked data showed black
women were more likely to present with stage IV disease compared to white women (42.1% versus
33.5%) (Howell et al., 2013). This result is consistent with another study based on earlier SEER
data (1988-2001), suggesting a significantly higher proportion of African Americans diagnosed at
stages III and IV disease compared to whites (74.8% versus 70.1%) (Chan, et al., 2008). However,
another study based on SEER-Medicare linked 1992-1999 data found the percentage of ovarian
cancer late stage diagnose (stage III and IV) was slightly higher in whites than African Americans
(71.6% versus 69.7%) (Du, et al., 2008). Furthermore, a case-control study based on data collected
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in Illinois in 1994-1998 showed no significant difference in stage at diagnosis between African
American and Caucasian women (Kim, Dolecek, & Davis, 2010).
Emerging studies also indicate racial disparities in ovarian cancer treatment. For example,
analysis of 1992-1999 SEER-Medicare linked data showed that compared with Caucasians,
significantly lower percentage of African-Americans received chemotherapy for ovarian cancer
treatment (Du, et al., 2008). According to a meta-analysis, white women are 1.17 times more likely
to receive any form of surgical treatment for ovarian cancer than African Americans (Terplan, et
al., 2009).
Although ovarian cancer mortality rates are slightly higher for white women than for AfricanAmerican women (Ovarian Cancer National Alliance, 2013), one study suggests that the 5-year
disease-specific survival of whites is significantly higher (44.1% versus 40.7%) than AfricanAmericans (Chan, et al., 2008). According to an analysis of the SEER 1973-2008 database the
disparities in ovarian cancer survival outcome has increased over the past three decades (Terplan,
et al., 2012). However, an earlier study based on the 1992-1999 SEER data found no significant
racial disparities in survival outcome between African-American and Caucasian women after
adjusting for tumor characteristics, treatment, and socio-demographic factors (Du, Sun, Milam,
Bodurka, & Fang, 2008).
When examining racial disparities in ovarian cancer diagnosis, treatment, and survival
outcomes, most previous studies mainly focused on comparison between African American and
Caucasian subpopulations. Very few studies included Hispanics, the largest and fastest growing
minority ethnic group in the U.S. One study based on the 2000-2004 SEER data indicated that
compared to non-Hispanic whites (NHWs) and non-Hispanic blacks (NHBs), Hispanic women
were more likely to be diagnosed with ovarian cancer at a younger age and earlier stage, and had
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a statistically significantly longer median survival (Ibeanu & Diaz-Montes, 2013). However, given
the rapid growth of Hispanic population, especially in rural areas and small town (The Housing
Assistance Council, 2012), it remains unknown whether Hispanic patients still have better survival
outcomes than NHWs and NHBs.
Age
Age can also contribute to health disparities. Poorer prognosis and worse health outcomes
among older persons may be attributed to several reasons. First, financial concerns might be one
of the barriers to accessing needed healthcare services, because the majority of elderly population
lives on fixed income and may not be able to cover their unanticipated healthcare costs. Second,
increasing risks of comorbidities and complications may inhibit elderly to choose or adhere to
required invasive therapies such as surgery and chemotherapy. Thirdly, they may also face some
physical challenges (e.g., due to impaired mobility, disordered cognition, or lack of transportation)
for accessing or asking for necessary healthcare services. Additionally, compared to younger
population, older people may have fewer opportunities to access necessary health information via
different media channels, such as Internet. Thus, older people are at a disadvantage in terms of
accessing health related information in order to identify symptoms and to seek appropriate
healthcare services.
Regarding ovarian cancer disparities by age, the receipt of cancer treatment is influenced by
patients’ age. For example, based on 2005 Australian Cancer Registries records, increasing age is
associated with non-receipt of chemotherapy, and one possible explanation is that older women
may have higher rates of toxicity with chemotherapy compared with younger women (Jordan et
al., 2013). A retrospective cohort study conducted in Denmark in 2005-2006, found that compared
with patients less than 70 years, elderly patients were also less likely to receive primary surgery
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(Jørgensen et al., 2012). Based on an analysis of the 1988-2001 SEER data, compared with older
ovarian cancer patients (i.e. those aged > 60 years), younger patients (i.e. those aged < 30 years)
had a significantly higher 5-year cancer survival rate (78.8% versus 35.3%), and this survival
advantage remained even after adjusting for race, stage, grade, and surgical treatment (Chan et al.,
2006). In another study based on a statewide Maryland hospital discharge data, no significant
differences in the number of comorbidities and intensive care unit length of stay were found
between women aged over 80 years and their younger counterparts. However, the 30-day mortality
rate was found to be 2.3 times higher for the older group compared with the younger group (DíazMontes et al., 2005).
Insurance Status
Insurance status is another important contributor to ovarian cancer disparities. Lack of health
insurance has long been linked to negative outcomes for many diseases. According to a study of
cancer outcomes based on the National Cancer Database with records from 12 sites, patients who
were uninsured or had Medicaid insurance were diagnosed with more advanced disease than
privately insured patients (Halpern et al., 2008). In another study, patients from counties with lower
uninsured rates had longer median survival, and county uninsured rate was also associated with
the stage at diagnosis for all cancers (Smith et al., 2013).
Additionally, there is a difference in insurance status by race/ethnicity. Compared to white
ovarian cancer patients, African-American patients were more likely to have Federal payer status
(Medicaid or Medicare) and less likely to have commercial insurance payer status (Bristow,
Zahurak, & Ibeanu, 2011). Previous studies also reported higher mortality for Medicare and
Medicaid patients compared to privately insured patients (LaPar et al., 2010). According to the
2012 NHIS data, Hispanic persons aged less than 65 years (32%) were more than twice as likely
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as non-Hispanic persons in the same group (14%) to be uninsured (CDC, 2014).
However, despite the association between insurance status and race/ethnicity, to what extent
the insurance status can contribute to the racial disparities in ovarian cancer remains unknown. For
instance, based on the 1998-2004 US National Cancer Database, for general cancer patients,
irrespective of insurance status, black and Hispanic patients had an increased risk of advanced
stage disease (stages III or IV) at diagnosis (Halpern, et al., 2008). While in another study, public
insurance was found to be associated with an increased hazard of ovarian cancer mortality and
disease recurrence independent of race (Mishka Terplan, Temkin, Tergas, & Lengyel, 2008).
Marital Status
Being married has long be linked with improved health status and decreased mortality
(Johnson, Backlund, Sorlie, & Loveless, 2000; Sorlie, Backlund, & Keller, 1995). According to a
study focusing on the impact of marital status on cancer outcomes, based on the 2004-2008 SEER
data, for cancer patients of the top 10 lethal cancer diseases (including ovarian cancer), unmarried
patients were at significantly higher risk of presentation with metastatic cancer, undertreatment,
and death resulting from their cancer (Aizer et al., 2013).
Few studies have reported the effect of marital status on ovarian cancer disparities in diagnosis,
treatment and survival outcomes. A study based on 1988-2006 SEER data indicated that being
married was independently associated with improved survival in women with ovarian cancer, with
adjustment for race, age, histology, stage, grade, and surgical treatment (Mahdi et al., 2013).
However, it is uncertain whether the effects remain after controlling for socioeconomic
environment.

21

Contextual-level Factors
Rural/Urban Residence
The population in rural and small town America increased by roughly 3.5 million between
2000 and 2010. More than half of all rural and small town population growth in the last decade is
attributable to Hispanics. In rural and small town areas, the Hispanic population increased by 1.9
million or 46 percent between 2000 and 2010, surpassing African Americans (8.2 percent) as the
largest minority group in rural and small town areas (The Housing Assistance Council, 2012).
With the rapid increase of minority population in rural areas, it is important to analyze the
rural-urban and racial patterns in ovarian cancer disparity. Such analysis allows us to quantify and
potentially reduce ovarian cancer-related health disparities between the least and most burdened
subpopulations.
The rural/urban disparity in health may be related to different lifestyles leading to different
levels of exposure to risk factors, unequal access to healthcare services, and different quality of
healthcare services and availability of the diagnostic tools and treatment required. Compared with
people who live in urban areas, people who live in rural areas may have lower accessibility to
health care and face longer travel times and lower access to specialized care (Chan, Hart, &
Goodman, 2006).
Previous research yield inconsistent results on influence of rural and urban residence on
ovarian cancer outcomes. A study conducted in Poznan, Poland during 2004-2011, suggest urban
disadvantage. According to this study, compared with women who live in small towns and rural
areas, several ovarian cancer risk factors, such as lower median parity and experienced menarche
at an earlier age, were found to be more common among women in large cities. However, no
rural/urban differences in stage at diagnosis or tumor type and size were found (Szpurek,
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Moszynski, Szubert, & Sajdak, 2013). Several other studies suggested opposite results. One study
in Denmark found greater risk of long diagnostic delays in rural areas (Robinson, Christensen,
Ottesen, & Krasnik, 2011); and a study conducted in Australia suggested that rural residence was
associated with non-receipt of chemotherapy (Jordan, et al., 2013). None of the studies to date
have focused on ovarian cancer disparities by rural/urban residence in the U.S.
Socioeconomic Status
Socioeconomic Status (SES) is defined as a composite measure that typically incorporates
economic, social, and work status. Economic status is measured by income. Social status is
measured by education, and work status is measured by occupation (CDC, 2014a). Individuallevel socioeconomic status has long be associated with disparities in health outcomes and
healthcare accessibility. For example, a person with more education is more likely to get a wellpaid job and have health insurance, and people who have higher incomes and health insurance are
more likely to get preventive services and the right treatment (CDC, 2014b). However, emerging
studies suggest the independent effects of contextual-level (such as county-level and communitylevel) socioeconomic status on health disparity. This may imply that the higher contextual-level
SES can confer risk of diseases and reduce healthcare accessibility regardless of individuals’ own
SES. For instance, according to a longitudinal survey based on nationally representative
households sampling, living in disadvantaged neighborhood (characterized as high percentage of
residents below poverty line, high percentage of unemployment, and high percentage of residents
with no high school diploma or GED) reduced the likelihood of having a usual source of care and
increased the likelihood of having unmet medical need. This association remained to be
statistically significant after controlling for individual-level characteristics (Kirby & Kaneda,
2005). According to a longitudinal study conducted in Netherlands, living in a neighborhood with
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a high percentage of unemployed/disabled or poor persons was associated with increased mortality,
and the effects remained even after controlling for individual socioeconomic status (Bosma, van
de Mheen, Borsboom, & Mackenbach, 2001).
As it relates to cancer, based on an analysis using SEER 1975-2000 data, for several major
types of cancers combined (but not including ovarian cancer), residents of poorer counties (with
greater or equal to 20% of the population below the poverty line) had higher age-adjusted death
rate and lower 5-year survival rate compared with more affluent counties (Ward et al., 2004). The
contextual effect of SES on disparities in breast cancer and cervical cancer have been well
established (Breen & Figueroa, 1996; Coughlin, et al., 2008; Robert et al., 2004). However, few
studies focused on the association between contextual-level SES and ovarian cancer disparities in
diagnosis, treatment, and survival outcomes. Furthermore, based on systematic review of previous
studies, the pattern of association between cancer mortality and SES (measured at individual or
contextual levels) may vary for specific cancers (Singh, Williams, Siahpush, & Mulhollen, 2012).
For instance, higher SES was found to be associated with lower rates of lung, stomach, cervical,
esophageal, oropharyngeal, and liver cancer mortality and higher rates of breast cancer and
melanoma (Singh, et al., 2012). As a result, it remains uncertain whether high contextual-level SES
has positive effect on ovarian cancer diagnosis, treatment, and survival.
To the best of my knowledge, racial/ethnic disparities in ovarian cancer diagnosis,
treatment and survival outcome using up to date national level cancer registry data have not been
examined. It also remains uncertain whether racial/ethnic disparities in ovarian cancer have
changed over the last decade. There is lack of studies focusing on contribution of both individualand contextual-level factors on ovarian cancer disparities. Previous studies have produced
inconsistent results on the association of the aforementioned factors with ovarian cancer outcomes.
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Findings from the current study will narrow the gap in ovarian cancer research by identifying
social factors and mechanisms contributing to disparities in health care access and health outcomes.
By identifying the subpopulations which suffer an excessive ovarian cancer burden, the study may
provide insights on how to modify currently existing health policies (e.g., on medical resource
allocation and public insurance reimbursement and coverage) and to develop health promotion
programs specifically targeting hard-to-reach populations (e.g., women living in disadvantaged
neighborhoods or minority groups with language barriers).
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CHAPTER 3
METHODOLOGY
Study Design
This was an observational, retrospective, cross-sectional study of a population-based
cancer registry database. Demographic, pathological, diagnosis, treatment, and survival
information from women diagnosed with malignant ovarian cancer from 2001 to 2012 was
extracted from the SEER Program of the National Cancer Institute (NCI). Patients diagnosed
before age of 18, had a prior malignancy, and those not diagnosed with microscopic confirmation
or have unknown diagnostic confirmation were excluded. The information obtained was not
individually identifiable, and as a result, the study was exempt from the Georgia Southern
Institutional Review Board approval.

Secondary Data Source
The SEER program collects cancer incidence and survival data from 18 population-based
cancer registries that represent approximately 27.8% of the U.S. population and is a premier
source for cancer statistics in the United States (National Cancer Institute, 2015e). The
geographic areas (registries) which are covered include San Francisco-Oakland SMSA,
Connecticut, Detroit (Metropolitan), Hawaii, Iowa, New Mexico, Seattle (Puget Sound), Utah,
Atlanta (Metropolitan), San Jose-Monterey, Los Angeles, Alaska Natives, Rural Georgia,
California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Greater Georgia
(National Cancer Institute, 2015e). The SEER 18 Regs Research data include adjustments for
areas impacted by hurricanes Katrina and Rita (National Cancer Institute, 2015e). United States
Census 2000 and 2007-2011 data were used for county-level SES variables (US Census Bureau
2007-2011).
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Study Variables
Main outcome variables included the stage of ovarian cancer at diagnosis, receipt of
surgery treatment, and survival time. The stage of ovarian cancer at diagnosis was classified
according to the American Joint Committee on Cancer classification system as stage 0 (in situ), I
(cancer is limited to the ovary or ovaries), II (growth of the cancer involves one or both ovaries
with pelvic extension), III (the cancer has spread beyond the pelvis to the lining of the abdomen
or the cancer has spread to lymph nodes), IV (the cancer has spread to organs located outside of
the peritoneal cavity) (National Cancer Institute, 2013). For the purposes of this study, the stage
of diagnosis was further dichotomized into non-advanced stage (stages 0, I, II) and advanced
stage (stages III and IV). Surgery treatment information was measured as receipt of surgery
(yes/no). The event in the time-to-event/survival analyses was ovarian cancer-cause specific
death within 5 years since ovarian cancer diagnosis, and survival time was defined as the time
from the time of ovarian cancer diagnosis till the ovarian cancer-cause specific death or the
cutoff time for follow-up (Dec 31, 2012). Ovarian cancer patients who died of other causes, or
died of ovarian cancer but after more than 5 years since ovarian cancer diagnosis were treated as
censored cases. The survival outcome was measured as 5-year ovarian cancer-cause specific
mortality and reported as Hazard Ratio (HR).
Other individual-level factors obtained from SEER included age at diagnosis which was
categorized into five categories (18-45 years/46-55 years/56-65 years/66-75 years/older than 76
years), race/ethnicity (NHW/ NHB/Hispanic/Other), marital status (married/not married),
insurance status (insured/ uninsured) and tumor pathological characteristics. According to the
International Classification of Diseases O-2 codes, tumor grade providing clinic-pathologic
information, was classified as well- differentiated, moderately differentiated, poorly
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differentiated, undifferentiated and unknown (National Cancer Institute, 2013). Major histology
types were classified as clear cell, mucinous, serous, endometrioid, other, or not otherwise
specified (NOS), based on the International Classification of Diseases O-3 codes.
Contextual-level variables included residence in a metro/nonmetro county and countylevel SES status. According to the rural-urban continuum code (RUCC) classification system
(United States Department of Agriculture, 2013), counties were classified as metro or nonmetro,
using the Federal Information Processing Standards [FIPS] codes. Based on the RUCC
classification system, counties with RUCC codes ≤ 3 (counties in metro areas of fewer than
250,000 population, 250,000 population or more) were defined as metro counties, and counties
with RUCC codes 4-9 (counties adjacent or not adjacent to a metro area and with urban population
of 2,500 or more or with completely rural or less than 2,500 urban population) were defined as
nonmetro counties (United States Department of Agriculture, 2013). County-level SES variables
included education, employment and poverty level. They were accessed through the SEER*Stat
Datasets measured at ratio level, and were calculated based on 2000 Census Data and 20072011Census American Community Survey (ACS) 5-year files (National Cancer Institute,
2015c).The county-level Census data were matched with the individual-level SEER data by county
FIPS codes. Patients diagnosed from the year of 2000-2006 were matched with the 2000 census
data, and those diagnosed from the year of 2007-2011 were matched with the 2007-2011 census
data. The county-level SES measurements include county education (i.e. percentage of a county
population with less than 9th grade education); county employment (i.e. percentage of persons
aged 16 and over who are unemployed in a county), and county poverty (i.e. percentage of persons
in a county whose incomes are below the 100% federal poverty level threshold (U.S. Department
of Health & Human Services, 2013). Each of these county SES percentage measures were sorted
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and categorized into quartiles (highest/upper-middle/lower-middle/lowest) when included into
models for analysis. For each of the three county SES quartile measures, counties in a higher
quartile have a superior county level SES. Collinearity among contextual-level factors was
assessed, its lack was confirmed with VIFs < 2.5.

Data Analysis
All individual- and contextual-level data were extracted using the 8.2.1 SEER*Stat
Software (National Cancer Institute, 2015f). Statistical analyses were performed using the Stata
SE 14.0 statistical software (College Station, TX) and Joinpoint trend analysis software version
4.2.0.1. (National Cancer Institute, 2015d). Descriptive statistics were used to describe the
distribution of individual-level socio demographic and tumor pathological characteristics, and
contextual-level factors. X-square tests of independence and analysis of variance (ANOVA)
were applied to assess the difference in distribution of each of these characteristics among
selected cases by race/ethnicity.
Multilevel binary logistic regression analyses were used to assess the effect of race and
ethnicity on stage diagnosis and receipt of surgery adjusted for individual-level and county-level
variables. Models included a random intercept for a county of residence; while the rest of the
variables were included as fixed effect. To identify factors contribute to the racial/ethnic
disparities, sub analysis using multilevel binary logistic regression were then conducted stratified
by race/ethnicity subgroups (NHW, NHB, and Hispanic). Average predicted margins and
marginal effects were calculated from multilevel logistic regression analysis with adjustment for
random effect and interaction effect. Adjusted probability estimates for advanced stage diagnosis
and receipt of surgery treatment were reported based on each of the logistic regressions.
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The Cox proportional hazards model with shared frailty (i.e. multilevel model) was used
to assess racial/ethnic disparities in ovarian cancer-cause specific mortality and to identify
factors contributing to the disparities. The proportional hazards assumption was assessed by
graphing the scaled Schoenfeld residuals on function of time, and testing the significance of
interaction between the variables of interest and time.
Because insurance status information was only available for patients diagnosed in and
after 2007, when insurance status was added into each of the logistic regression and Cox
proportional hazards models, only cases diagnosed in 2007 and later were included in the
analyses. For all the logistic regression and Cox proportional hazards models, significance of
interaction terms between race/ethnicity and variables of interest were checked, and significant
interaction terms were included in the final models.
To test whether the racial/ethnic disparities in stage at diagnosis, receipt of surgery
treatment and ovarian cancer-cause specific mortality have changed over time, cases were
grouped into 12 cohorts by year of diagnosis, and for each of the cohorts, logistic regressions
were used to estimate odds ratios for advanced stage diagnosis and receipt of surgery, and
survival analysis was used to estimate hazard ratios for ovarian cancer cause-specific death. The
odds ratios and hazard ratios were estimated comparing each of the two racial/ethnic groups
(NHW vs. NHB, NHW vs. Hispanics, and NHB vs. Hispanics), while adjusting for individualand contextual-level confounders. The estimated odds ratios and hazard ratios for the 12 cohorts
were then analyzed using the Joinpoint trend analysis software. This software takes trend data
(odds ratios and hazard ratios) as dependent variables, year of diagnosis as independent variable,
and fits the simplest Joinpoint model that the data allow. This analysis was applied to test
whether an apparent change in trend was statistically significant. The test of significance applies
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a Monte Carlo Permutation method (National Cancer Institute, 2015d). All tests were two-tailed.
A significant level was set at P <0.05.
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CHAPTER 4
RESULTS
Descriptive Characteristics
There were 69,444 women diagnosed with malignant ovarian cancer between 2001 and
2012. Among those ovarian cancer patients, 669 cases were excluded because of age (less than
18 years old at diagnosis); 5,316 cases were excluded because of having no microscopic or
unknown diagnostic confirmation; 8,686 cases were excluded because of prior malignancy
diagnosis, and 193 cases were eliminated due to unknown race/ethnicity status. The final study
sample included 54,580 ovarian cancer patients, of whom 39,726 (72.78%) were NHWs, 4,295
(7.87%) were NHBs, 6,256 (11.46%) were Hispanic, and 4,303 (7.88%) were of other
race/ethnicity (e.g. American Indian/Alaska Native and Asian or Pacific Islander).
Descriptive characteristics are presented in Table 1 by race/ethnicity. NHW patients were
diagnosed at an older age (mean age=62.55, p<0.001)) compared with NHBs (mean age=59.57),
Hispanics (mean age=55.63) and patients of other race/ethnicity (mean age=55.88). The
prevalence of ovarian cancer by groups of age at diagnosis also significantly varied across
race/ethnicity groups (p<0.001). NHW (25.06%) and NHB (24.05%) patients were more likely to
be diagnosed at age of 55-64 compared with other age groups, but Hispanics were more likely to
be diagnosed at the age of 18-45 (25.69%). NHW (54.24%) patients had a larger proportion of
married women compared with NHBs (31.18%) and Hispanics (49.30%), but the proportion of
being married was the highest in patients from Other racial/ethnic groups (58.62%) (p<0.001).
NHW patients had the highest health insurance coverage rate (96.80%), followed by patients
from Other racial/ethnic groups (95.36%), NHB (92.83%) and Hispanic patients (90.44%)
(p<0.001). NHB patients (72.60%) were more likely to be diagnosed at advanced stage compared
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with patients from NHW (71.29%), Hispanic (66.66%), and Other racial/ethnic groups (61.10%)
(p<0.001). Patients from Other racial/ethnic groups (85.65%) had the highest rate of receiving
surgery treatment, followed by Hispanics (82.29%), NHW (81.63%), and NHBs (69.18%) had
the lowest rate for surgery treatment (p<0.001). Regarding tumor pathological characteristics, the
prevalence of tumor grade and histology also significantly varied by race/ethnicity (p<0.001).
In terms of contextual-level characteristics, higher percentage of NHW patients (13.10%)
lived in nonmetro areas compared to patients in NHB (9.39%), Hispanic (3.96%) and Other
racial/ethnic groups (5.06%) (p<0.001). More Hispanic patients (48.91%) lived in counties with
lowest quartile rank of county-level education compared to patients in NHW (19.54%), NHB
(21.86%), and Other racial/ethnic groups (27.96%) (p<0.001). NHB patients were more likely to
live in counties characterized as lowest SES when measured by unemployment (NHB: 37.81%,
NHW: 18.72%, Hispanic: 24.34%, other: 12.53, p<0.001) and poverty rate (NHB: 35.51%, NHW
19.58%, Hispanic: 28.23%, other: 15.64%, p<0.001).
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Table 1
Characteristics of Ovarian Cancer Cases, 2001-2012, SEER (N=54,580)
Characteristics

Age at diagnosis
(mean)
Age at diagnosis
(Group)
18-45
45-54
55-64
65-74
>=74
Marital status
Not married
Married
Insurance b
Uninsured
Insured
Stage
Non-advanced
Advanced
Surgery
No
Yes
Grade
Well differentiated
Moderately
differentiated
Poorly differentiated
Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell
Other or unspecified
Contextual-level
Factors

Non-Hispanic
White
(n=39,726)
%a
62.55

Non-Hispanic
Black
(n=4,295)
%
59.57

Hispanic

Other

p-value

(n=6,256)
%
55.63

(n=4,303)
%
55.88

<0.001
<0.001

11.37
20.22
25.06
21.63
21.73

17.88
20.58
24.05
20.88
16.60

25.69
23.91
21.44
17.04
11.92

23.66
27.70
22.08
14.85
11.71
<0.001

45.76
54.24

68.82
31.18

50.70
49.30

41.38
58.62

3.20
96.80

7.17
92.83

9.56
90.44

4.64
95.36

<0.001

<0.001
28.71
71.29

27.40
72.60

33.34
66.66

38.90
61.10

18.37
81.63

30.82
69.18

17.71
82.29

14.35
85.65

6.60
13.42

5.77
11.06

8.07
13.16

7.81
14.06

34.29
12.97
32.72

29.29
8.87
45.01

30.66
10.55
37.56

33.07
13.15
31.91

<0.001
<0.001

<0.001
46.19
5.48
9.59
5.14
33.60

37.30
6.38
6.10
2.51
47.71

36.69
7.18
10.10
4.51
38.52

35.77
7.90
11.85
11.71
32.77
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Characteristics

Metro/nonmetro
Residence c
Metro
Nonmetro
County education d
Highest
Upper-middle
Lower-middle
Lowest
County employment e
Highest
Upper-middle
Lower-middle
Lowest
County poverty f
Highest
Upper-middle
Lower-middle
Lowest

Non-Hispanic
White
(n=39,726)
%a

Non-Hispanic
Black
(n=4,295)
%

Hispanic

Other

(n=6,256)
%

(n=4,303)
%

p-value

<0.001
86.90
13.10

90.61
9.39

96.04
3.96

94.94
5.06

30.12
26.35
23.98
19.54

16.07
37.46
24.61
21.86

7.24
13.63
30.21
48.91

13.87
19.38
38.79
27.96

<0.001

<0.001
29.58
25.87
25.83
18.72

14.41
17.63
30.15
37.81

12.18
20.46
43.01
24.34

26.63
23.38
37.46
12.53
<0.001

28.20
27.11
25.10
19.58

13.13
17.97
33.39
35.51

13.20
19.17
39.40
28.23

27.28
33.35
23.73
15.64

Notes: a Unadjusted percentage b Only for cases diagnosed in 2007 and after. c Metro vs. nonmetro categories are based
on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S.
Department of Agriculture. d Sorted by percentage of a county population with less than 9th grade education in
ascending order, and categorized into quartiles. e Sorted by percentage of persons aged 16 and over who are
unemployed in a county in ascending order, and categorized into quartiles. f Sorted by percentage of persons in a
county whose incomes are below the 100% federal poverty level threshold in ascending order, and categorized into
quartiles.

Advanced Stage Diagnosis
Racial/Ethnic Disparities in Advanced Stage Diagnosis
As shown in Table 2 (Odds Ratios are presented in Appendix F: Table 2.2), adjusting for
all the variables listed in Table 1, year of diagnosis, county random effect, and interaction effect
of race/ethnicity and county-level employment, significant racial/ethnic disparities in advanced
stage diagnosis only exist in counties with county-level employment rate ranked in the highest
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and lower-middle quartiles. Significant differences in advanced stage diagnosis between NHB
and NHW patients were only observed in counties with the employment rate ranked in the
highest quartile, and in such counties, NHB patients (75.44%, 95%CI: 72.35% – 78.53%) were
significantly more likely to present with advanced ovarian cancer at the time of diagnosis
compared to NHW patients (69.52%, 95%CI: 68.58% - 70.46%). For patients living in counties
that ranked in lower-middle quartile for employment rate, patients from Other racial/ethnic
groups (66.91%, 95%CI: 64.80% - 69.01%) had significantly lower probability of advanced
stage diagnosis compared with their NHW counterparts (70.65%, 95%CI: 69.76% - 71.54%).
The prevalence of advanced stage diagnosis among Hispanic patients did not significantly differ
from the prevalence in NHW patients.

Table 2
Adjusted Prevalence of Advanced Stage Diagnosis and Receipt of Surgery a
Study Variables
Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Age at diagnosis
18-45
46-55
56-65
66-75
>=76
Marital status
Not married
Married

Advanced Stage Diagnosis
(N=54,580)
% b (95%CI )

Receipt of Surgery
(N=54,580)
% b (95%CI )

–
–
–
–

83.40 (83.04 – 83.76) ref
77.65 (76.73 – 78.58)*
81.96 (81.16 – 82.76)*
81.94 (80.92 – 82.97)*

55.73 (54.64 – 56.83) ref
65.85 (65.01 – 66.69)*
71.94 (71.18 – 72.69)*
75.77 (74.97 – 76.57)*
79.41 (78.60 – 80.22)*

93.81 (93.20 – 94.41) ref
88.79 (88.16 – 89.42)*
85.26 (84.68 – 85.84)*
81.51 (80.88 – 82.13)*
71.86 (71.11 – 72.62)*

70.70 (70.15 – 71.26) ref
69.81 (69.28 – 70.33)*

81.13 (80.70 – 81.56) ref
84.31 (83.89 – 84.72)*
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Study Variables
Stage
Non-advanced
Advanced
Grade
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell
Other or unspecified
Interaction: race/ethnicity *
county employment
County employment: highest
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
County employment: uppermiddle
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
County employment: lowermiddle
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
County employment: lowest
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Contextual-level factors:
Metro/nonmetro residence c

Advanced Stage Diagnosis
(N=54,580)
% b (95%CI )

Receipt of Surgery
(N=54,580)
% b (95%CI )

–
–

94.29 (93.84 – 94.74) ref
79.32 (78.88 – 79.75)*

43.97 (42.21 – 45.74) ref
60.95 (59.84 – 62.06)*
74.85 (74.19 – 75.50)*
73.93 (72.85 – 75.00)*
73.88 (73.21 – 74.56)*

91.91 (90.34 – 93.47) ref
92.59 (91.78 – 93.40)*
91.93 (91.50 – 92.37)*
94.21 (93.60 – 94.83)*
68.57 (67.83 – 69.32)*

82.57 (82.04 – 83.09) ref
51.69 (49.84 – 53.55)*
46.12 (44.61 – 47.62)*
39.93 (38.16 – 41.69)*
69.70 (68.96 – 70.43)*

89.40 (88.98 – 89.83) ref
84.11 (82.78 – 85.45)*
92.00 (90.70 – 93.29)*
92.83 (91.64 – 94.03)*
74.02 (73.40 – 74.64)*

69.52 (68.58 – 70.46) ref
75.44 (72.35 – 78.53)*
67.82 (64.75 – 70.88)
71.28 (68.84 – 73.72)

–
–
–
–

70.52 (69.63 – 71.40) ref
72.22 (69.34 – 75.11)
70.64 (68.39 – 72.90)
69.29 (66.71 – 71.86)

–
–
–
–

70.65 (69.76 – 71.54) ref
71.33 (69.06 – 73.61)
71.13 (69.51 – 72.76)
66.91 (64.80 – 69.01)*

–
–
–
–

69.91 (68.76 – 71.06) ref
70.55 (68.37 – 72.73)
70.83 (68.67 – 73.00)
69.71 (66.10 – 73.31)

–
–
–
–
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Study Variables
Metro
Nonmetro
County education d
Highest
Upper-middle
Lower-middle
Lowest
County employment e
Highest
Upper-middle
Lower-middle
Lowest
County poverty f
Highest
Upper-middle
Lower-middle
Lowest
Random effect
County variance

Advanced Stage Diagnosis
(N=54,580)
% b (95%CI )
70.27 (69.84 – 70.70) ref
69.88 (68.73 – 71.02)

Receipt of Surgery
(N=54,580)
% b (95%CI )
82.66 (82.29 – 83.02) ref
82.16 (81.37 – 82.95)

70.91 (69.98 – 71.83) ref
69.90 (69.06 – 70.73)
70.41 (69.59 – 71.22)
69.67 (68.72 – 70.62)

82.50 (81.77 – 83.23) ref
82.76 (82.11 – 83.41)
82.40 (81.70 – 83.11)
82.73 (82.06 – 83.40)

–
–
–
–

82.80 (82.15 – 83.46) ref
82.74 (82.11 – 83.37)
82.78 (82.22 – 83.34)
81.98 (81.21 – 82.74)

69.00 (67.96 – 70.04) ref
69.72 (68.85 – 70.58)
70.93 (70.12 – 71.75)*
71.34 (70.37 – 72.30)*

83.17 (82.35 – 84.00) ref
82.41 (81.70 – 83.13)
82.50 (81.88 – 83.11)
82.34 (81.65 – 83.04)

0.0070

0.0451*

Notes: a Adjusted for all the variables listed in the table, year of diagnosis, interactions between race/ethnicity and
county employment, and county random effects. b Average adjusted predicted probabilities. c Metro vs. nonmetro
categories are based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research
Service, U.S. Department of Agriculture. d Sorted by percentage of a county population with less than 9 th grade
education in ascending order, and categorized into quartiles. e Sorted by percentage of persons aged 16 and over who
are unemployed in a county in ascending order, and categorized into quartiles. f Sorted by percentage of persons in a
county whose incomes are below the 100% federal poverty level threshold in ascending order, and categorized into
quartiles.
CI, confidence interval. ref reference group. * p<0.05

Factors Associated with Disparities in Advanced Stage Diagnosis
Based on adjusted analysis, the probability of advanced stage diagnosis significantly
increased by age. On average, women being diagnosed at the ages of 76 or older had a 23.68%
increased probability of being diagnosed at advanced stage compared to women being diagnosed
between the ages of 18 to 45 (p<0.05). On average, a significantly smaller percentage of married

38

women (69.81%, 95%CI: 69.28% - 70.33%) were diagnosed at advanced stage compared to
unmarried women (70.70%, 95%CI: 70.15% - 71.26%) (p<0.05).
With respect to contextual-level factors, although not statistically significant, patients
living in nonmetro counties (69.88%, %95CI: 68.73% – 71.02%) had lower probability of being
diagnosed at advanced stage, compared to patients living in metro counties (70.27%, 95%CI:
69.84% – 70.70%). The average probability of advanced stage diagnosis also did not
significantly vary by county-level education. Interaction between race/ethnicity and county-level
employment was found to be significantly associated with advanced stage diagnosis. The effect
of county-level employment rate varied by race/ethnicity. When considering the county-level
poverty status, patients from the lower-middle (70.93%, 95%CI: 70.12% – 71.75%) and lowest
quartile counties (71.34%, 95%CI: 70.37% – 72.30%) had a significantly increased probability
of advanced stage diagnosis compared to patients from the highest quartile counties (69.00%,
95%CI: 67.96% – 70.04%). Based on the results of a sub analysis, when adding insurance status
to the original model, and only including cases diagnosed in 2007-2012, on average, the
probability of advanced stage diagnosis did not significantly differ by insurance status
(uninsured: 69.24% vs. insured: 68.74%) (Appendix A: Table 2.1). The average probability of
advanced stage diagnosis also did not vary significantly across counties (variance: 0.0068,
p=1.0000). However, when comparing model (results not shown) adjusted for individual-level
factors only with the full model (i.e., the one with both individual- and contextual-level factors),
county random effect (variance) decreased from 0.0087 to 0.0068.
Factors Contributing to Racial/Ethnic Disparities in Advanced Stage Diagnosis
Results based on the sub analysis stratified by race/ethnicity group are shown in Table 3
(Odds Ratios are presented in Appendix G: Table 3.2). Age at diagnosis was positively
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associated with advanced stage diagnosis for patients in all three racial/ethnic groups. The
association between marital status and advanced stage diagnosis was statistically significant for
NHW patients (married: 71.04% vs. unmarried: 72.00%, p<0.05), but not for NHB and Hispanic
patients. Insurance status was not significantly associated with advanced stage diagnosis for
patients in either of the three groups (Appendix B: Table 3.1). For patients in all three groups,
probability of being diagnosed at advanced stage did not significantly vary by metro/nonmetro
residence or county-level education status. County-level employment was significantly
associated with advanced stage diagnosis in NHB patients, but not in NHW and Hispanic
patients. NHB patients from counties with employment rate ranked in the lower-middle (72.19%,
95%CI: 69.63% – 74.75%) and lowest quartiles (70.93, 95%CI: 68.41% – 73.45%) had a
significantly lower probability of being diagnosed at advanced stage compared with their
counterparts from the highest quartile counties (77.45, 95%CI: 73.98% – 80.92%). However,
while not statistically significant, NHW and Hispanic patients from counties with lower
employment rate had higher prevalence of advanced stage diagnosis compared with their
counterparts in the highest quartile counties. NHW patients from poorer counties were more
likely to be diagnosed with advanced stage compared with their counterparts from less poorer
counties. However, this association was not significant in NHB and Hispanic patients. Stage of
diagnosis did not significantly differ by counties for all three racial/ethnic groups.
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Table 3
Factors Contributing to Racial/Ethnic Disparities in Advanced Stage Diagnosis and Receipt of Surgery, by Race/Ethnicity a
Study Variables

Age at diagnosis
18-45
46-55
56-65
66-75
>=76
Marital status
Not married
Married
Stage
Non-advanced
Advanced

Advanced Stage Diagnosis
% b (95%CI)
Non-Hispanic
Non-Hispanic
Hispanic
White
Black
(n=39,726)
(n=4,295)
(n=6,256)

Non-Hispanic
White
(n=39,726)

Receipt of Surgery
% b (95%CI)
Non-Hispanic
Black
(n=4,295)

(n=6,256)

Hispanic

56.29ref
(54.88 – 57.7)
66.58*
(65.6 – 67.57)
72.29*
(71.44 – 73.13)
76.03*
(75.14 – 76.92)
79.73*
(78.85 – 80.61)

58.85 ref
(55.42 – 62.27)
69.16
(66.20 – 72.12)
75.60*
(72.99 – 78.21)
78.25*
(75.50 – 81.01)
82.84*
(80.02 – 85.67)

53.60 ref
(51.13 – 56.07)
64.71*
(62.28 – 67.14)
72.04*
(69.61 – 74.47)
75.61*
(72.96 – 78.26)
77.40*
(74.28 – 80.52)

94.28 ref
(93.46 – 95.10)
90.21*
(89.46 – 90.97)
86.30*
(85.63 – 86.98)
82.89*
(82.18 – 83.6)
73.40*
(72.56 – 74.240)

85.07 ref
(82.50 – 87.64)
77.50*
(75.05 – 79.94)
71.15*
(68.88 – 73.43)
65.54*
(63.08 – 67.99)
56.35*
(53.31 – 59.39)

94.00 ref
(92.74 – 95.27)
85.98*
(84.33 – 87.62)
85.01*
(83.43 – 86.58)
80.33*
(78.54 – 82.13)
69.00*
(66.31 – 71.70)

72 .00 ref
(71.37 – 72.63)
71.04*
(70.47 – 71.62)

73.42 ref
(71.91 – 74.94)
71.24
(68.92 – 73.56)

67.06 ref
(65.41 – 68.71)
65.84
(64.16 – 67.52)

81.36 ref
(80.84 – 81.87)
84.74*
(84.26 – 85.22)

69.35 ref
(68.07 – 70.62)
73.95*
(72.03 – 75.88)

82.97 ref
(82.01 – 83.93)
84.93*
(83.89 – 85.97)

-

-

-

-

-

-

94.12 ref
(93.56 – 94.68)
80.14*
(79.64 – 80.65)

89.11 ref
(87.14 – 91.08)
65.12*
(63.76 – 66.49)

96.44 ref
(95.45 – 97.44)
79.43*
(78.42 – 80.43)
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Study Variables

Grade
Well differentiated
Moderately
differentiated
Poorly
differentiated
Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell
Other or
unspecified

Advanced Stage Diagnosis
% b (95%CI)
Non-Hispanic
Non-Hispanic
Hispanic
White
Black
(n=39,726)
(n=4,295)
(n=6,256)

Non-Hispanic
White
(n=39,726)

Receipt of Surgery
% b (95%CI)
Non-Hispanic
Black
(n=4,295)

(n=6,256)

45.97 ref
(43.87 – 48.06)
62.05*
(60.77 – 63.32)
75.79*
(75.06 – 76.52)
74.78*
(73.58 – 75.98)
75.39*
(74.61 – 76.16)

42.15 ref
(35.52 – 48.78)
64.22*
(59.94 – 68.50)
76.18*
(73.77 – 78.60)
76.93*
(72.48 – 81.37)
76.29*
(74.31 – 78.28)

39.43 ref
(34.72 – 44.14)
60.21*
(56.92 – 63.49)
71.66*
(69.52 – 73.81)
72.03*
(68.46 – 75.61)
69.12*
(67.10 – 71.14)

90.86 ref
(88.94 – 92.78)
92.43
(91.47 – 93.40)
92.20
(91.69 – 92.71)
94.86*
(94.17 – 95.56)
68.51*
(67.59 – 69.43)

93.05 ref
(87.16 – 98.95)
88.26*
(84.78 – 91.75)
84.70*
(82.75 – 86.64)
86.11*
(82.75 – 89.48)
54.06
(51.96 – 56.16)

94.88 ref
(91.07 – 98.70)
93.61
(91.47 – 95.74)
92.69
(91.55 – 93.83)
93.04
(91.20 – 94.88)
71.72*
(70.09 – 73.35)

83.19 ref
(82.62 – 83.77)
51.76
(49.50 – 54.03)
45.38*
(43.63 – 47.14)
39.53*
(37.42 – 41.63)
71.36*
(70.50 – 72.22)

83.68 ref
(81.83 – 85.52)
60.76*
(54.88 – 66.65)
49.80*
(43.48 – 56.12)
50.66*
(41.61 – 59.71)
70.03*
(67.91 – 72.16)

80.26 ref
(78.54 – 81.98)
50.79*
(45.93 – 55.64)
45.73*
(41.50 – 49.96)
39.91*
(34.39 – 45.43)
64.08*
(61.92 – 66.23)

89.65 ref
(89.15 – 90.15)
84.42*
(82.79 – 86.04)
91.85*
(90.31 – 93.39)
93.60*
(92.21 – 95.00)
74.25*
(73.50 – 75.00)

80.73 ref
(78.97 – 82.50)
72.04*
(66.71 – 77.37)
83.11
(76.79 – 89.43)
79.64
(71.42 – 87.86)
61.69*
(59.87 – 63.52)

90.33 ref
(89.28 – 91.38)
86.24*
(82.97 – 89.50)
94.59*
(91.35 – 97.82)
91.37
(87.99 – 94.74)
75.52*
(74.07 – 76.97)

Hispanic
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Study Variables

Contextual-level
factors:
Metro/nonmetro
residence c
Metro
Nonmetro
County education d
Highest
Upper-middle
Lower-middle
Lowest
County employment e
Highest
Upper-middle
Lower-middle
Lowest

Advanced Stage Diagnosis
% b (95%CI)
Non-Hispanic
Non-Hispanic
Hispanic
White
Black
(n=39,726)
(n=4,295)
(n=6,256)

Non-Hispanic
White
(n=39,726)

Receipt of Surgery
% b (95%CI)
Non-Hispanic
Black
(n=4,295)

(n=6,256)

71.50 ref
(71.03 – 71.97)
71.26
(70.07 – 72.45)

73.09 ref
(71.77 – 74.42)
68.96
(63.99 – 73.93)

66.49 ref
(65.20 – 67.77)
65.58
(59.53 – 71.64)

82.98 ref
(82.53 – 83.43)
83.08
(82.25 – 83.91)

70.87 ref
(69.75 – 71.98)
69.18
(65.34 – 73.02)

83.90 ref
(83.20 – 84.61)
82.17
(78.22 – 86.11)

72.18 ref
(71.31 – 73.05)
71.2
(70.35 – 72.05)
71.32
(70.33 – 72.32)
70.91
(69.78 – 72.04)

71.47 ref
(67.71 – 75.22)
71.74
(69.48 – 73.99)
74.80
(72.26 – 77.34)
73.01
(69.87 – 76.15)

66.94 ref
(62.14 – 71.74)
64.74
(61.26 – 68.22)
67.20
(64.41 – 69.99)
66.39
(64.29 – 68.49)

83.00 ref
(82.26 – 83.75)
83.24
(82.54 – 83.95)
82.88
(82.08 – 83.68)
82.78
(81.81 – 83.76)

69.41 ref
(66.29 – 72.54)
72.10
(70.27 – 73.93)
71.03
(68.89 – 73.17)
68.83
(66.18 – 71.47)

84.46 ref
(81.25 – 87.67)
83.30
(81.12 – 85.47)
83.23
(81.68 – 84.79)
84.24
(83.06 – 85.42)

70.82 ref
(69.96 – 71.69)
71.76
(70.88 – 72.64)
71.91
(71.04 – 72.79)
71.49
(70.38 – 72.60)

77.45 ref
(73.98 – 80.92)
73.52
(70.29 – 76.75)
72.19*
(69.63 – 74.75)
70.93*
(68.41 – 73.45)

64.94 ref
(60.83 – 69.04)
67.91
(64.71 – 71.10)
66.48
(64.48 – 68.48)
65.88
(63.02 – 68.75)

83.10 ref
(82.41 – 83.80)
83.17
(82.48 – 83.87)
82.76
(82.00 – 83.52)
82.93
(82.06 – 83.80)

71.38 ref
(68.25 – 74.50)
70.71
(67.98 – 73.45)
73.39
(71.37 – 75.41)
68.19
(66.09 – 70.29)

85.86 ref
(83.43 – 88.29)
84.68
(82.67 – 86.69)
83.79
(82.59 – 85.00)
82.41*
(80.81 – 84.00)

Hispanic
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Study Variables

County poverty f
Highest
Upper-middle
Lower-middle
Lowest
Random effect
County variance

Advanced Stage Diagnosis
% b (95%CI)
Non-Hispanic
Non-Hispanic
Hispanic
White
Black
(n=39,726)
(n=4,295)
(n=6,256)

Non-Hispanic
White
(n=39,726)

Receipt of Surgery
% b (95%CI)
Non-Hispanic
Black
(n=4,295)

(n=6,256)

70.44 ref
(69.43 – 71.45)
71.23
(70.32 – 72.14)
72.04*
(71.13 – 72.95)
72.53*
(71.40 – 73.66)

70.80 ref
(66.44 – 75.16)
71.45
(67.92 – 74.98)
72.25
(69.94 – 74.55)
74.48
(72.20 – 76.77)

63.49 ref
(59.07 – 67.91)
63.65
(59.9 – 67.41)
66.94
(64.78 – 69.11)
69.00
(66.31 – 71.70)

83.70 ref
(82.84 – 84.56)
82.94
(82.18 – 83.71)
83.02
(82.29 – 83.75)
82.11*
(81.22 – 83.00)

70.31 ref
(66.77 – 73.85)
68.59
(65.63 – 71.55)
70.75
(68.85 – 72.64)
71.81
(69.87 – 73.75)

84.15 ref
(81.50 – 86.81)
84.38
(82.17 – 86.60)
83.27
(82.03 – 84.50)
84.14
(82.55 – 85.73)

0.0031

<0.0001

0.0248

0.0527*

<0.0001

<0.0001

Hispanic

Notes: a Adjusted for all the variables listed in the table, year of diagnosis and county random effects. b Average adjusted predicted probabilities. c Metro vs. nonmetro
categories are based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. Department of Agriculture. d
Sorted by percentage of a county population with less than 9th grade education in ascending order, and categorized into quartiles. e Sorted by percentage of persons
aged 16 and over who are unemployed in a county in ascending order, and categorized into quartiles. f Sorted by percentage of persons in a county whose incomes
are below the 100% federal poverty level threshold in ascending order, and categorized into quartiles.
CI, confidence interval. ref reference group. * p<0.05
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Receipt of Surgery Treatment
Racial/Ethnic Disparities in Receipt of Surgery Treatment
Receipt of surgery treatment varied by race/ethnicity. On average, NHW patients had the
highest probability of receiving surgery treatment (83.40%, 95%CI: 83.04% - 83.76%) followed
by Hispanic patients (81.96%, 95%CI: 81.16% - 82.76%) and patients in Other racial/ethnic
groups (81.94%, 95%CI: 80.92% - 82.97%). NHB patients (77.65%, 95%CI: 76.73% - 78.58%)
had the lowest probability of receiving surgery (p’s<0.05).
Factors Associated with Disparities in Receipt of Surgery
Age at diagnosis was positively and significantly associated with receipt of surgery, with
the youngest group (18-45 years old) having the highest surgery rate (93.81, 95%CI: 93.20% 94.41%), and the oldest group (older than 76) having the lowest surgery rate (71.86%, 95%:
71.11% - 72.62%) (p<0.05). Married patients were significantly more likely to receive surgery
treatment compared with their unmarried counterparts (81.13% vs. 84.31%, p<0.05). If patients
were diagnosed at advanced stage, the probability for receiving surgery treatment significantly
decreased by 14.97 percentage points (94.29% vs. 79.32%, p<0.05). Being insured significantly
increased the probability of receiving surgery treatment by 5.24 percentage points (84.29% vs.
80.94%, p<0.05) (Appendix A: Table 2.1). No interaction between race/ethnicity and other
variables was significantly associated with receipt of surgery.
Contextual-level factors including metro/nonmetro residence and all the county-level
SES indicators were not significantly associated with receipt of surgery. However, the
probability of receiving surgery treatment varied significantly by county (variance: 0.0451,
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p=0.0004). When comparing model adjusted for individual-level factors only (results not shown)
with the full model, the county random effect (variance) decreased from 0.0526 to 0.0451.
Factors Contributing to Racial/Ethnic Disparities in Receipt of Surgery
Results based on the sub analysis regarding receipt of surgery stratified by race/ethnicity
are reported in Table 3 (Odds Ratios are presented in Appendix G: Table 3.2). For patients in all
three racial/ethnic groups, age at diagnosis was negatively associated with the probability of
receiving surgery treatment. However, when comparing differences in average probability of
surgery receipt between the youngest group (18-45 years old) and oldest group (older than 76
years), the probability decreased by 20.22 percentage points (94.28% vs. 73.40%, p<0.05) in
NHW patients, 28.72 percentage points (85.07% vs. 56.35%, p<0.05) in NHB patients, and
25.00 percentage points (94.00% vs. 69.00%, p<0.05) in Hispanic patients. Being married was
positively and significantly associated with higher probability of receiving surgery treatment for
patients in all three groups (p’s<0.05). Based on sub analysis including insurance status, the
association between receipt of surgery treatment and insurance status was only found to be
significant among NHW and Hispanic patients, but not among NHB patients (Appendix B: Table
3.1). Receipt of surgery was also significantly associated with stage at diagnosis for patients in
all three groups. When diagnosed at advanced (vs. early) stage, the probability of receiving
surgery treatment decreased by 13.98 percentage points (94.12% vs. 80.14%, p<0.05) for NHW
patients, 29.33 percentage points (89.11% vs. 65.12%, p<0.05) for NHB patients, and 17.01
percentage points (96.44% vs. 79.43%, p<0.05) for Hispanic patients.
For patients in all racial/ethnic groups, receipt of surgery was not significantly associated
with metro/nonmetro residence and county-level education. For Hispanic patients, those living in
counties in the lowest quartile rank of county employment rate were significantly less likely to
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receive surgery treatment compared to their counterparts in counties in the highest quartile rank
of county employment rate (82.41% vs. 85.86%, p<0.05). However, the association between
county-level employment rate and receipt of surgery was not significant for NHB and Hispanic
patients. County-level poverty was significantly associated with receipt of surgery for NHW
patients, and patients from the counties in the lowest quartile had significantly lower probability
of receiving surgery compared with their counterparts from counties in the highest quartile
(82.11% vs. 83.70%, p<0.05). However, this association was also not found to be significant in
other two racial/ethnic groups. The average predicted probabilities of receiving surgery
significantly varied across counties for NHW patients (variance: 0.0527, p<0.0001), but not for
NHB and Hispanic patients.
Ovarian Cancer-Cause Specific Mortality
Racial/Ethnic Disparities in Ovarian Cancer-Cause Specific Mortality
Results based on Cox proportional hazards model with shared frailty are shown in Table
4. The 5-year ovarian cancer-cause specific mortality varied significantly by counties (variance:
0.0042, p=0.0010). When comparing model adjusted for individual-level factors only (results not
shown) with the full model, county random effect (variance) decreased from 0.0055 to 0.0042.
However, since the county variance was so small and not clinically meaningful, the reported
Hazard Ratio was not adjusted for random effects. Adjusting for all the variables listed in Table
1 and year of diagnosis, NHB patients had a 1.24-fold increased hazards of ovarian cancer causespecific death compared to NHW patients (95% CI: 1.18 – 1.30, p<0.05). While not statistically
significant, Hispanic patients and patients in Other racial/ethnic groups had 2% (95%CI: 0.94 –
1.03) and 4% (95%CI: 0.90 – 1.02) decreased hazards than NHW patients, respectively.
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Table 4
Adjusted Hazard Ratios for Ovarian Cancer-Cause Specific Mortality a
Study Variables

Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Age at diagnosis
18-45
46-55
56-65
66-75
>=76
Marital status
Not married
Married
Stage
Non-advanced
Advanced
Surgery
No
Yes
Grade
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell
Other or unspecified
Contextual-level factors:
Metro/nonmetro residence b
Metro
Nonmetro
County education c
Highest

Ovarian Cancer-Cause Specific
Mortality
(N=54,580)
HR (95%CI)
Ref
1.24 (1.18 – 1.30)*
0.98 (0.94 – 1.03)
0.96 (0.90 – 1.02)
Ref
1.33 (1.25 – 1.41)*
1.51 (1.43 – 1.60)*
1.84 (1.74 – 1.95)*
2.57 (2.42 – 2.73)*
Ref
0.86 (0.83 – 0.88)*
Ref
4.66 (4.43 – 4.91)*
Ref
0.32 (0.31 – 0.33)*
Ref
1.91 (1.72 – 2.13)
2.33 (2.10 – 2.58)
2.32 (2.09 – 2.59)
2.15 (1.94 – 2.39)
Ref
1.63 (1.52 – 1.75)*
0.76 (0.70 – 0.81)*
1.31 (1.21 – 1.41)*
1.23 (1.19 – 1.27)*

Ref
1.09 (1.04 – 1.14)*
Ref
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Study Variables

Upper-middle
Lower-middle
Lowest
County employment d
Highest
Upper-middle
Lower-middle
Lowest
County poverty e
Highest
Upper-middle
Lower-middle
Lowest
Random effect
County variance

Ovarian Cancer-Cause Specific
Mortality
(N=54,580)
HR (95%CI)
0.99 (0.94 – 1.04)
0.98 (0.93 – 1.03)
1.01 (0.95 – 1.08)
Ref
0.93 (0.89 – 0.97)*
0.94 (0.89 – 0.99)*
0.96 (0.90 – 1.01)
Ref
1.06 (1.00 – 1.11)*
1.07 (1.01 – 1.14)*
1.09 (1.02 – 1.16)*
0.0042*

Notes: a Adjusted for all the variables listed in the table, year of diagnosis and county random effects. b Metro vs.
nonmetro categories are based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic
Research Service, U.S. Department of Agriculture. c Sorted by percentage of a county population with less than 9 th
grade education in ascending order, and categorized into quartiles. d Sorted by percentage of persons aged 16 and
over who are unemployed in a county in ascending order, and categorized into quartiles. e Sorted by percentage of
persons in a county whose incomes are below the 100% federal poverty level threshold in ascending order, and
categorized into quartiles.
HR, hazard ratio. CI, confidence interval. ref reference group. * p<0.05

Factors Associated with Disparities in Ovarian Cancer-Specific Mortality
The risk of death due to ovarian cancer within five years of diagnosis significantly
increased with age at diagnosis. Patients who were diagnosed after the age of 76 years had a
2.57-fold increased hazards of death than patients diagnosed at 18-45 years old (95%CI: 2.42 –
2.73, p<0.05). Being married was a significant protective factor against ovarian cancer death:
married patients were 14% less likely to die from ovarian cancer compared with unmarried
patients (HR: 0.86, 95%CI: 0.83- 0.88, p<0.05). Being diagnosed with advanced stage
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significantly increased the hazards of ovarian cancer death by 4.66-fold (95%CI: .4.43 – 4.91,
p<0.05). If surgery treatment had been received, the risk of death due to ovarian cancer
decreased by 68% (HR: 0.32, 95%CI: 0.31 – 0.33, p<0.05). No interaction other than interaction
between race/ethnicity and insurance was significantly associated with ovarian cancer-cause
specific mortality (Appendix C: Table 4.1).
With respect to contextual-level factors, patients living in nonmetro counties had higher
risk of death due to ovarian cancer compared with their counterparts living in metro counties
(HR: 1.09, 95%CI: 1.04 – 1.14, p<0.05). Ovarian cancer cause-specific mortality did not differ
by county-level education. Regarding county-level employment rate, patients from counties in
upper-middle (HR: 0.93, 95%CI: 0.89 – 0.97, p<0.05) and lower-middle (0.94, 95%CI: 0.89 –
0.99, p<0.05) quartiles were less likely to die from ovarian cancer compared with patients from
counties in the highest quartile; however, the risk of death did not significantly differ between
the lowest quartile (HR: 0.96, 95%CI: 0.90 – 1.01) and the highest quartile. Ovarian cancer
cause-specific mortality also significantly varied by county-level poverty, and patients living in
counties in lower rank had increased risk of death compared with their counterparts living in
counties in higher rank (p <0.05).
Factors Contributing to Racial/Ethnic Disparities in Ovarian Cancer- Specific Mortality
As shown in Table 5, for patients in all three racial/ethnic groups, the hazards of dying
from ovarian cancer was positively associated with increasing age. However, when comparing
the hazards of death between patients diagnosed at age older than 76 and patients diagnosed
between 18-45 years old, the hazards of ovarian cancer cause-specific death increased by 2.56fold for NHW patients (95%CI: 2.38 – 2.76, p<0.05), 2.40-fold for NHB patients (95%CI: 2.01 –
2.86, p<0.05), and 2.91- fold for Hispanic patients (95%CI: 2.47 – 3.43, p<0.05). The protective
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effect of being married was only significant in NHW patients (HR: 0.84, 95%CI: 0.82 – 0.87,
p<0.05) and NHB patients (HR: 0.82, 95%CI: 0.74 – 0.91, p<0.05) but not in Hispanic patients
(HR: 0.98, 95%CI: 0.90 – 1.07). The effect of insurance status on ovarian cancer mortality also
varied by race/ethnicity. Being insured significantly decreased the risk of death due to ovarian
cancer for NHW patients (HR: 0.79, 95%CI: 0.68 – 0.93, p<0.05). However, although not
significant, being insured was found to be associated with increased risk of ovarian cancer death
for NHB patients (HR: 1.36, 95%CI: 0.99 – 1.88, p>0.05) and for Hispanic patients (HR: 1.03,
95%CI: 0.80 – 1.34) (Appendix D: Table 5.1). Being diagnosed at advanced stage was a
significant risk factor for ovarian cancer cause-specific death for patients in all three racial/ethnic
groups. However, when diagnosed at advanced (vs. early) stage, the hazards of death due to
ovarian cancer significantly increased by 4.65- fold in NHW patients (95%CI: 4.38 – 4.95,
p<0.05), 3.78-fold in NHB patients (95%CI: 3.24 – 4.41, p<0.05), and 5.98 in Hispanic patients
(95%CI: 5.05 – 7.09, p<0.05). Receipt of surgery significantly decreased risk of ovarian cancer
death for patients in all three racial/ethnic groups, and the effect sizes were similar across the
racial/ethnic groups.
In regard to contextual-level factors, survival difference by metro/nonmetro residence
was significant for NHW patients (HR: 1.09 95%CI: 1.04 – 1.15, p<0.05), but not for NHB and
Hispanic patients. County-level education was not significantly associated with ovarian cancercause specific mortality for patients in either of the three groups. County-level employment rate
was significantly associated with ovarian cancer-cause specific mortality in NHW patients, and
patients from counties in the upper-middle (HR: 0.93, 95%CI: 0.88 – 0.97, p<0.05), lowermiddle (HR: 0.93, 95%CI: 0.88 – 0.98, p<0.05) and lowest quartile (HR: 0.93, 95%CI: 0.87 –
0.99, p<0.05) had significantly higher mortality compared with patients from the highest quartile
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counties, respectively. However, these associations were not significant for patients from other
racial/ethnic groups. Similarly, the association between county-level poverty and ovarian cancercause specific mortality was significant only in NHW patients, and patients from lower quartile
counties had higher risk of ovarian cancer death than patients from the highest quartile counties
(p’s<0.05). Ovarian cancer-cause specific mortality significantly varied by county, but only for
NHW patients (variance: 0.0044, p=0.0010).

Table 5
Factors Contributing to Disparities in Ovarian Cancer-Cause Specific Mortality, by
Race/Ethnicity a
Study Variables

Age at diagnosis
18-45
46-55
56-65
66-75
>=76
Marital status
Not married
Married
Stage
Non-advanced
Advanced
Surgery
No
Yes
Grade
Well differentiated
Moderately
differentiated
Poorly differentiated

Ovarian Cancer-Cause Specific Mortality
HR (95%CI)
Non–Hispanic White Non–Hispanic Black
Hispanic
(n=39,726)
(n=4,295)
(n=6,256)
Ref.
1.29 (1.19 – 1.39)*
1.51 (1.40 – 1.62)*
1.82 (1.69 – 1.96)*
2.56 (2.38 – 2.76)*

Ref.
1.58 (1.33 – 1.88)*
1.61 (1.36 – 1.91)*
1.90 (1.60 – 2.25)*
2.40 (2.01 – 2.86)*

Ref.
1.36 (1.17 – 1.59)*
1.61 (1.38 – 1.87)*
2.01 (1.72 – 2.34)*
2.91 (2.47 – 3.43)*

Ref.
0.84 (0.82 – 0.87)*

Ref.
0.82 (0.74 – 0.91)*

Ref.
0.98 (0.90 – 1.07)

Ref.
4.65 (4.38 – 4.95)*

Ref.
3.78 (3.24 – 4.41)*

Ref.
5.98 (5.05 – 7.09)*

Ref.
0.32 (0.31 – 0.34)*

Ref.
0.33 (0.30 – 0.38)*

Ref.
0.30 (0.27 – 0.35)*

Ref.
1.84 (1.63 – 2.08)*

Ref.
2.48 (1.68 – 3.67)*

Ref.
1.87 (1.35 – 2.59)*

2.22 (1.97 – 2.49)*

2.79 (1.92 – 4.07)*

2.37 (1.74 – 3.24)*
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Study Variables

Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell
Other or unspecified
Contextual-level factors:
Metro/nonmetro
residence b
Metro
Nonmetro
County education c
Highest
Upper-middle
Lower-middle
Lowest
County employment d
Highest
Upper-middle
Lower-middle
Lowest
County poverty e
Highest
Upper-middle
Lower-middle
Lowest
Random effect
County variance

Ovarian Cancer-Cause Specific Mortality
HR (95%CI)
Non–Hispanic White Non–Hispanic Black
Hispanic
(n=39,726)
(n=4,295)
(n=6,256)
2.21 (1.95 – 2.50)*
2.98 (2.00 – 4.44)*
2.27 (1.63 – 3.16)*
2.10 (1.87 – 2.37)*
2.59 (1.78 – 3.78)*
1.85 (1.35 – 2.53)*
Ref.
1.51 (1.39 – 1.65)*
0.72 (0.66 – 0.78)*
1.26 (1.15 – 1.38)*
1.19 (1.15 – 1.24)*

Ref.
2.30 (1.89 – 2.81)*
0.86 (0.67 – 1.09)
1.70 (1.25 – 2.30)*
1.31 (1.17 – 1.46)*

Ref.
2.07 (1.70 – 2.52)*
0.97 (0.79 – 1.20)
1.77 (1.39 – 2.25)*
1.41 (1.27 – 1.57)*

Ref.
1.09 (1.04 – 1.15)*

Ref.
1.05 (0.89 – 1.25)

Ref.
1.20 (0.97 – 1.5)

Ref.
0.98 (0.93 – 1.04)
0.97 (0.92 – 1.03)
0.99 (0.93 – 1.06)

Ref.
0.98 (0.83 – 1.15)
0.99 (0.83 – 1.17)
1.03 (0.85 – 1.24)

Ref.
1.02 (0.82 – 1.26)
1.05 (0.86 – 1.28)
1.10 (0.88 – 1.37)

Ref.
0.93 (0.88 – 0.97)*
0.93 (0.88 – 0.98)*
0.93 (0.87 – 0.99)*

Ref.
0.93 (0.78 – 1.11)
1.12 (0.95 – 1.31)
1.13 (0.95 – 1.35)

Ref.
0.92 (0.78 – 1.09)
0.86 (0.71 – 1.04)
0.84 (0.69 – 1.02)

Ref.
1.06 (1.00 – 1.12)
1.09 (1.02 – 1.16)*
1.14 (1.06 – 1.23)*

Ref.
1.05 (0.87 – 1.26)
0.99 (0.82 – 1.19)
0.92 (0.76 – 1.12)

Ref.
1.07 (0.90 – 1.28)
1.07 (0.88 – 1.30)
1.16 (0.94 – 1.44)

0.0044*

0.0032

<0.0001

Notes: a Adjusted for all the variables listed in the table, year of diagnosis and county random effects. b Metro vs.
nonmetro categories are based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic
Research Service, U.S. Department of Agriculture. c Sorted by percentage of a county population with less than 9th
grade education in ascending order, and categorized into quartiles. d Sorted by percentage of persons aged 16 and
over who are unemployed in a county in ascending order, and categorized into quartiles. e Sorted by percentage of
persons in a county whose incomes are below the 100% federal poverty level threshold in ascending order, and
categorized into quartiles.
HR, hazard ratio. CI, confidence interval. Ref., reference group. * p<0.05
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Changes in Racial Disparities over Time
Results of Joinpoint regression analysis which tested the change in racial/ethnic
disparities in ovarian cancer diagnosis, surgery treatment and survival over time are presented in
Figures 1-3. Adjusting for variables listed in Table 1, except for insurance status, racial/ethnic
disparities in advanced stage diagnosis, receipt of surgery and ovarian cancer-cause specific
mortality did not vary significantly from 2001 to 2012 (all p’s >0.05).
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Figure 1. Racial/Ethnic Disparities in Advanced Stage Diagnosis: Trend over Years 2001-2012
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Figure 2. Racial/Ethnic Disparities in Receipt of Surgery: Trend over Years 2001-2012
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Figure 3. Racial/Ethnic Disparities in Ovarian Cancer-Cause Specific Mortality: Trend over
Years 2001-2012
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CHAPTER 5
DISCUSSION
This study examined racial/ethnic disparities in ovarian cancer advanced stage diagnosis,
receipt of surgery treatment, and survival outcome, and assessed trend in racial/ethnic disparities
over 12 years using longitudinal panel dataset. Several individual- and contextual-level factors
which contribute to those racial/ethnic disparities were identified. Based on most recent national
cancer registry data, this study updates the knowledge base on changes in ovarian cancer
racial/ethnic disparities over time.
Racial/ethnic disparities in ovarian cancer diagnosis, treatment, and survival may be
attributed to multiple factors, such as tumor biology, genetic differences, healthcare accessibility
and quality, or a combination of those factors. This study focused on assessing effects of
individual- and contextual-level socio demographic and economic characteristics on ovarian
cancer racial/ethnic disparities, while adjusting for tumor pathological differences.

Racial/Ethnic Disparities
Compared to NHB patients, NHB patients have a significant disadvantage in ovarian
cancer, specifically in advanced stage diagnosis, receipt of surgery treatment, and ovarian causespecific mortality. This finding is consistent with many previous studies based on national- or statelevel data (Chan, et al., 2008; Howell, et al., 2013; Morris, Sands, & Smith, 2010; Terplan, et al.,
2012). Two studies had either contrary or insignificant findings regarding stage of diagnosis
between the two racial groups; however, the results were based on unadjusted analysis (Du, et al.,
2008; Kim, et al., 2010). In the current study on NHB patients living in counties with the
employment rate ranked in the first quartile were less likely to be diagnosed at advanced stage.
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This finding suggests that certain contextual-level characteristics, such as county-level
employment rate or other related factors, may be contributing to racial/ethnic disparities in ovarian
cancer diagnosis.
The study suggests no significant differences in stage of diagnosis and survival between
Hispanic and NHW patients. However, Hispanic patients have a significantly lower probability of
receiving surgery treatment compared with NHW patients. Definitive conclusions regarding
ovarian cancer racial/ethnic disparities between Hispanic and Other racial/ethnic groups have not
been established in previous studies, primarily due to the limited data on ovarian cancer cases
among Hispanic women. One study based on 1996-2006 California Cancer Registry data found no
significant differences on stage of diagnosis between Hispanics and NHW. This finding is
consistent with my finding (Morris, et al., 2010). The current study also indicates that Hispanic
patients have the youngest mean age at diagnosis (55.63 years), followed by patients from Other
racial/ethnic groups (55.88 years), and NHBs (59.57 years). NHWs have the oldest mean age at
diagnosis (62.55 years). Based on 2000-2004 SEER 12 data, which included 1,215 Hispanic
ovarian cancer patients, Ibeanu and Diaz-Montes’s study (2005) also supports my result by
indicating that Hispanic are significantly more likely to be diagnosed at a younger age compared
to NHWs and NHBs. Findings of Ibeanu and Diaz-Montes that Hispanics patients were
significantly less likely to be diagnosed with ovarian cancer at advanced stage compared to NHW
patients was based on unadjusted analysis (Ibeanu and Diaz-Montes, 2005). Adjustment for
individual socio demographic characteristics, tumor pathological characteristics, metro/nonmetro
residence and county SES, the current study does not find a significant difference in ovarian cancer
advanced stage diagnosis between Hispanics and NHWs.
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Individual-Level Factors Contributing to Racial/Ethnic Disparities
Age
Being diagnosed at a younger age has long been associated with better health outcomes for
cancer patients. In the current study, younger age at diagnosis was found to be independently
associated with decreased risk of advanced stage diagnosis, increased probability of receiving
surgery treatment, and decreased hazards due to ovarian cancer. This age advantage remained in
all racial/ethnic subpopulations. However, to what extend age at diagnosis can affect each level of
the ovarian cancer continuum differs by race/ethnicity. For example, based on the stratified (by
race/ethnicity) and adjusted results, when comparing the probabilities of receiving surgery
treatment between women diagnosed at the age of 76 or older and those who were diagnosed
between 18-45 years, the differences in surgery rates between these two age groups are 20.00,
28.72 and 25.00 percentage points for NHW, NHB, and Hispanic patients, respectively. This result
indicates age at diagnosis has a stronger association with receipt of surgery for NHB patients and
Hispanic patients than NHW patients. In other words, compared to NHW patients, NHB and
Hispanic patients may be more likely to forgo surgery treatment due to age consideration. Similarly,
differences in age at diagnosis may also contribute differently to ovarian cancer cause-specific
death by racial/ethnic groups. Based on the results of Cox proportional hazard models stratified by
race/ethnicity, when comparing women diagnosed at age of 76 or older to those who were
diagnosed between the ages of 18-45, the ovarian cancer-cause specific hazard ratios were 2.56,
2.40, and 2.91 for NHWs, NHBs, and Hispanics, respectively, which indicates that being
diagnosed at an older age may be a stronger risk factor for ovarian cancer-cause specific death for
Hispanic patients compared to their NHW and NHB counterparts.
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Marital Status
Similar to age, in this study, marital status was also found to be a significant factor for
ovarian cancer early stage of diagnosis, receipt of surgery, and survival. This finding is consistent
with and supported by a study based on 2004-2008 SEER data, which revealed the advantages of
being married in cancer diagnosis, treatment, and survival for patients of the top 10 lethal cancers
(Aizer, et al., 2013). One study has emphasized the survival advantage for married ovarian cancer
patients and indicated that advantage might be attributed to psychosocial support potentially
altering immune function (Mahdi, et al., 2013). Another possible explanation regarding the
marriage protective effect on general health is related to greater economic resources (Trovato &
Lauris, 1989), which might be related to increased healthcare accessibility and higher quality of
life. The current study finds significant association between being married and decreased
probability of advance stage diagnosis, as well as increased probability of receiving surgery
treatment. However, because I could not control for individual-level social economic status,
whether this marriage advantage can be contributed to higher SES needs further examination.
A study based on the Health Retirement Survey data suggested about variation of
association between marital status and general health by race and ethnicity. Adjusted for SES and
baseline health status, compared to NHW women, for NHBs being married is significantly more
protective against the 2-year mortality (Beckett & Elliott, 2002). In the current study, as specific
to each level of the ovarian cancer continuum, variation in significance of association between
marital status and ovarian cancer diagnosis and survival is observed across racial/ethnic groups.
Being married is a significant protective factor for advanced stage diagnosis only for NHW patients,
but not for NHB and Hispanic groups. The protective effect on survival is only significant for
NHW and NHB patients, but not for the Hispanic patients. Similarly, whether this variation can be
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explained by individual- SES or difference in healthcare accessibility and quality still needs further
examination. Furthermore, because the sample sizes for NHB and Hispanics are relatively much
smaller compared with NHWs, the study findings need to be replicated on samples with larger
representation of NHB and Hispanic patients.
Insurance Status
Due to limited information on health insurance status, all the analysis with insurance status
were conducted using sub models with cases diagnosed in 2007 and later. Based on the primary
model which combined all racial/ethnic groups, being insured is significantly associated with
increased probability of receiving surgery, but when stratified by race/ethnicity, this association is
only significant among NHW and Hispanic patients (but not in NHB patients). However, being
covered by health insurance does not mean that the ovarian cancer surgery treatment procedures
are covered by insurance plan; the proportion of cost being covered may vary based on the
insurance types. For example, it has been reported that compared to NHWs, NHBs were more
likely to be publicly insured and less likely to have commercial insurance (Bristow, et al., 2011).
However, due to the small proportion of uninsured cases and lack of information on types of
insurance plan, this conclusion needs to be further confirmed in samples with higher proportion of
uninsured cases and with more specific information on insurance types. No significant association
between insurance status and the probability of advanced stage diagnosis is observed in either the
primary model or stratified models. I was not surprised to find the absence of significant
association between insurance status and advanced stage diagnosis, since ovarian cancer screening
tests were not generally recommended and applied to general population due to limited tests
specificity and potential harms, as a result, being health insured may not be a powerful factor to
promote effective ovarian cancer screening. Regarding insurance effect on survival outcome, the
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results from this study indicate interaction effect of race/ethnicity and insurance status. When
stratified by race/ethnicity, being insured was found to be a significant protective factor against
ovarian cancer-cause specific death for NHW patients, but significant risk factor for NHB patients;
and has no significant effect on survival for Hispanic patients. Similarly, one possible explanation
could still be the difference in type of insurance plan. For example, one study based on clinical
record suggested public insurance was associated with increased hazard of ovarian cancer
mortality (Mishka Terplan, et al., 2008).
Advanced Stage Diagnosis and Receipt of Surgery
Additionally, models examining ovarian cancer-cause specific mortality were adjusted for
advanced stage diagnosis and receipt of surgery. The results based on the primary model (with all
racial/ethnic groups) are consistent with previous studies; there is a significant risk effect for being
diagnosed at advanced stage, and a significant protective effect for receiving surgery treatment on
survival outcome. The beneficial effect on ovarian cancer survival from receiving surgery
treatment remained in stratified models, and the effect sizes were similar across racial/ethnic
groups. However, the association between advanced stage diagnosis and ovarian cancer survival
does varies across racial/ethnic groups. Based on the stratified models, adjusting for receipt of
surgery and other covariates, being diagnosed at advanced stage significantly increased ovarian
cancer death by 4.65-folds for NHW patients, 3.78-folds in NHB patients, and 5.98-folds in
Hispanic patients. Other potentially influencing factors such as genetic, biological, comorbidity
and other related factors are required to better explain variation in association between stage at
diagnosis and survival by race/ethnicity.
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Contextual-level Factors Contributing to Racial/ethnic Disparities
Metro/Nonmetro Residence
In this study, the metro/nonmetro residence was treated as a contextual-level factor, and a
study on metro/nonmetro differences was conceptually a rural/urban (the term which was used in
most other related studies) difference. This study used the terms metro/nonmetro to be consistent
with the RUCC classification system. Based on the adjusted results, metro/nonmetro residence is
not significantly associated with advanced stage diagnosis and receipt of surgery treatment in
either the primary model or any of the race/ethnicity stratified models. Living in nonmetro counties
is a significant protective factor against ovarian cancer specific death based on the primary model;
however, when stratified by race/ethnicity, this association is only found in NHW patients, but not
in other two groups. The finding on the nonmetro survival advantage is contrary to the
investigator’s initial hypothesis that ovarian cancer patients living in metro counties have lower
ovarian cancer mortality. This hypothesis was based on the fact that generally, people living in
metro areas tend to have better healthcare accessibility and quality. Based on the investigator’s
literature review, very few studies have reported on ovarian cancer disparities by rural/urban
residence, especially based on the U.S. population. Only one study based on the SEER-Medicare
linked database suggested ovarian cancer patients in rural areas were more likely to have surgery
at a low-volume hospital than residents of urban communities. However, according to this study,
hospital surgery volume was not significantly associated with ovarian cancer outcome (Schrag et
al., 2006). Yet, in a study conducted in Poland, living in urban areas was associated with being
exposed to increased ovarian cancer risk factors, such as lower parity, higher education level and
experiencing menarche at an earlier age (Szpurek, et al., 2013). Because the sample of the current
study consisted of a very small proportion of nonmetro residents (11.11%), and this proportion
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was even smaller among NHB (9.39%) and Hispanic (3.96%) patients, it is possible that the study
sample size for NHB and Hispanic patients may be not large enough to generate statistically
significant results. The small sample for minority patients from nonmetro areas may also indicate
that although more minority populations are majorly resident in rural area (The Housing Assistance
Council, 2012), the SEER cancer registry data mainly included minority patients living in urban
areas. In other words, cases which are diagnosed and treated in urban healthcare facilities are more
likely to be included into the cancer registry records.
County-level SES (Education, Employment and Poverty)
In this study, county-level SES was operationalized with three separate variables (rather
than an index): county-level education, employment, and poverty degree. The study results
indicate that ovarian cancer advanced stage diagnosis, receipt of surgery, and survival do not vary
significantly by county-level education.
Living in poorer counties is significantly associated with increased probability of advanced
stage diagnosis. However, this association is only significant in NHWs but not in NHBs and
Hispanics. Another interesting finding is that the association between county-level employment
and advanced stage diagnosis varies by race/ethnicity. Living in counties with lower employment
rate had a significant protective effect against advanced stage diagnosis for NHB patients; however,
although not statistically significant, lower county employment rate is a risk factor for advanced
stage diagnosis for NHW and Hispanic patients.
Receipt of surgery is not significantly associated with any of the county SES measurements.
Regarding the ovarian cancer cause-specific mortality, county-level employment and poverty are
significantly associated with ovarian cancer death for NHW patients but not for NHB and Hispanic
patients. While living in poorer counties is associated with higher ovarian cancer mortality, living
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in counties with lower employment is associated with lower risk ovarian cancer death.
The association between higher contextual-level SES and better health outcomes has been
well established by previous studies, as people living in higher contextual-level SES usually have
better access to healthcare services (CDC, 2014b; Kirby & Kaneda, 2005). On the contrary, several
studies have also indicated disadvantage of living in higher contextual-level SES community
(Robert, et al., 2004; Singh, et al., 2012). For instance, Robert et al found that compared to women
living in lower SES communities, those living in higher SES communities had greater odds of
having breast cancer (Robert, et al., 2004). Therefore, explanation of contextual-level SES effect
on health outcomes should not always focus on unequal access to healthcare services. In the current
study, the findings on the negative effect of living in counties with higher employment rate may
be explained by differences in exposure of other ovarian cancer risk factors such as lower parity
and higher education.

County Variance
Results of the multilevel analysis suggest the probability of advanced stage diagnosis does
not significantly vary by county in either primary model (i.e., adjusting for all racial/ethnic groups)
or models stratified by race/ethnicity. This study finds a significant but slight county variance in
surgery receipt and ovarian cancer-cause specific mortality; however, the minor and significant
county variance is only observed in NHW patients but not in other two racial/ethnic groups. The
county random effect decreases when contextual-level factors are added to the models, which
indicates that the variation of ovarian cancer outcomes at county level may be partially explained
by these contextual-level factors. However, since the ovarian cancer prevalence is relative low
compared to other major cancer diseases such as breast cancer and cervical cancer, the distribution
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of reported cases in certain counties might be rare, especially for minority patients which are
underrepresented in this study sample, therefore, a lack of statistical power due to limited minority
cases may contribute to the insignificant county variance in NHB and Hispanic subpopulations.

Racial/Ethnic Disparities Change over Time
This study does not find a significant change in ovarian cancer racial/ethnic disparities
from 2001 to 2012. Based on the Joinpoint trend analysis, when comparing the racial/ethnic ORs
and HRs for each two of the three racial/ethnic groups over time, no significant changes are found
between any of the two racial/ethnic group combinations. This result indicates that the extend of
racial/ethnic disparities in ovarian cancer advanced stage diagnosis, receipt of surgery treatment,
and survival has remained stable from 2001 to 2012 among NHW, NHB, and Hispanic patients.
To my knowledge, changes in prevalence of ovarian cancer advanced stage diagnosis and receipt
of surgery over time have not been examined by race/ethnicity. Terplan et al’s study based on
SEER 9 data assessed racial survival differences between NHW and NHB patients from 1973 to
2007 (M. Terplan, et al., 2012). During this study period, racial disparities in survival (adjusted for
registry, tumor stage and marital status) had been widened between the two racial groups due to
differences in the receipt of surgery. However, since HRs were measured by every five-year
diagnosis cohort, annual change in HRs, and cases diagnosed in recent years were not actually
assessed by this study. Although the current study period partially overlaps with the 1973-2007
study period, the two studies differ in measurement and assessment, thus, by including more recent
data, the current study yield different results: there is no significant change in racial/ethnic
disparities from 2001 to 2012. Because the data used in the current study did not contain
information on chemotherapy and newly emerged treatment such as antiangiogenic therapy, future
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studies should assess changes in ovarian cancer disparities related to other types of treatment.

Limitations and Strengths
This study had several limitations. First, it has been shown that the prevalence of BRCA1
and BRCA2 mutation, which was strongly associated with ovarian cancer development, can vary
by racial/ethnic groups in the U.S. (John et al., 2007; National Cancer Institute, 2015b). However,
family ovarian cancer history and genetic influence were not controlled for in this study due to
unavailability of such data. Second, because of the incomplete treatment information, it is types of
treatment other than surgery were not examined in this study. The current three main types of
treatment for ovarian cancer include surgery, chemotherapy and radiotherapy. Racial disparities
regarding the receipt of chemotherapy have been reported in previous studies (Du, et al., 2008).
However, since SEER data do not provide information on the receipt of chemotherapy, assessing
disparities in receipt of chemotherapy and its contribution to racial/ethnic disparities in ovarian
cancer outcomes is not possible in this study. Based on the SEER data, only less than 2 percent
ovarian cancer patients received radio therapy. Due to considerations of statistical power, this study
did not assess the effect of radiation therapy on ovarian cancer outcomes. Thirdly, individual
insurance status information was only available for patients diagnosed from the year of 2007 and
later. As a result, this study was not able to assess the effect of insurance status for cases diagnosed
earlier; thus, the insurance status was not adjusted in the trend analysis. Finally, an important
limitation of this study is the limited sample size of minority patients, especially NHB patients
which accounts for less than 8 percent of the total study population. When stratified by
race/ethnicity, the assessment of association between certain factors and interested outcomes might
be insignificant due to limited statistical power.
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This study also have several strengths. First, it is based on the most updated national level
cancer registry data which allowed for a large sample size for multivariate and multilevel statistical
analysis, and the large sample size also increased the representativeness of the study sample.
Second, the inclusion of multi-year cohorts defined by time of diagnosis enabled the analysis to
control for and study on time effects on interested outcomes.

Contributions
The current study updates the knowledge about racial/ethnic disparities in ovarian cancer
diagnosis, surgery treatment and survival based on most recent national-level cancer research data.
Furthermore, by applying a multilevel social ecological research approach, it provides new
evidence on the effect of contextual-level factors on ovarian cancer outcomes. It also provides new
insights into mechanisms through which racial/ethnic disparities in ovarian cancer are developed,
and updates information on the racial/ethnic disparities change over time. Finally, this study also
initiates several new future research endeavors to address the aforementioned limitations and to
further explore other potential individual- and contextual-level factors contributing to racial/ethnic
disparities in ovarian cancer diagnosis, treatment, and survival.

Conclusions and Implication
This study confirms that racial/ethnic disparities exist at each level of the ovarian cancer
continuum diagnosis, treatment, and survival, and the extent of these racial/ethnic disparities has
remained stable from 2001-2012. Both individual- and contextual-level factors contribute to the
ovarian cancer racial/ethnic disparities. The effect of these factors can varies by race/ethnicity, and
should be examined separate.
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As certain subpopulations experience excessive health burdens related to ovarian cancer,
multilevel efforts are needed to improve ovarian cancer diagnosis and treatment. An efficient way
to identify and target these vulnerable populations can be based on a combination of individuallevel and contextual-level factors associated with ovarian cancer outcomes. Specific policy
interventions should focus on subpopulations at a greater risk for ovarian cancer diagnosed at a
later stage, for forgoing surgery treatment (NHB and Hispanic patients); and ovarian cancer
mortality (e.g. Hispanic patients who were diagnosed at advanced stage). Potential policy
recommendation may include (1) developing or modifying insurance plans to encourage ovarian
cancer screening, and to improve reimbursement for potential treatments for populations at risk;
(2) developing standardized protocols and procedures for ovarian cancer treatment to reduce the
probability of forgoing treatment due to lack of information or healthcare resources. Future studies
should focus on exploring other factors which were not assessed in this study but may potentially
influence racial/ethnic disparities in ovarian cancer outcomes, such as family history, behavioral
factors, individual SES, and other types of treatment.
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APPENDICES
Appendix A: Table 2.1
Models with Insurance Status: Adjusted Prevalence of Advanced Stage Diagnosis and Receipt of
Surgery (N=27,539) a
Study Variables
Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Age at diagnosis
18-45
46-55
56-65
66-75
>=76
Marital status
Not married
Married
Insurance
Uninsured
Insured
Stage
Non-advanced
Advanced
Grade
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell
Other or unspecified
Interaction: race/ethnicity *
county employment
County employment: highest
Non-Hispanic White
Non-Hispanic Black

Advanced Stage Diagnosis
% b (95%CI)

Receipt of Surgery
% b (95%CI)

68.41 (67.79 – 69.03)ref
71.15 (69.24 – 73.06)*
69.11 (67.58 – 70.64)
69.15 (67.39 – 70.91)

83.27 (82.78 – 83.77) ref
78.27 (77.05 – 79.49)*
81.41 (80.30 – 82.52)*
82.34 (80.96 – 83.71)

53.86 (52.32 – 55.41) ref
64.17 (63.00 – 65.34)*
70.43 (69.42 – 71.45)*
74.36 (73.25 – 75.48)*
78.48 (77.32 – 79.65)*

94.81 (94.01 – 95.60) ref
89.21 (88.34 – 90.08)*
85.37 (84.56 – 86.18)*
80.85 (79.95 – 81.75)*
70.31 (69.21 – 71.41)*

69.01 (68.27 – 69.74) ref
68.54 (67.85 – 69.24)

80.94 (80.35 – 81.52) ref
84.29 (83.72 – 84.87)*

69.24 (66.95 – 71.52) ref
68.74 (68.23 – 69.25)

77.42 (75.37 – 79.47) ref
82.66 (82.20 – 83.12)*

–
–

93.62 (92.96 – 94.28) ref
79.36 (78.77 – 79.95)*

40.87 (38.31 – 43.43) ref
57.81 (56.13 – 59.49)*
72.35 (71.42 – 73.29)*
72.04 (70.66 – 73.43)*
73.59 (72.68 – 74.51)*

93.80 (91.65 – 95.95) ref
92.87 (91.59 – 94.14)
92.12 (91.50 – 92.74)
94.80 (94.03 – 95.58)
67.85 (66.80 – 68.90)*

81.40 (80.68 – 82.11) ref
47.49 (44.66 – 50.32)*
42.65 (40.42 – 44.89)*
38.64 (36.23 – 41.06)*
67.17 (66.14 – 68.20)*

88.06 (87.47 – 88.65) ref
84.72 (82.67 – 86.77)*
92.82 (90.88 – 94.76)*
93.27 (91.58 – 94.96)*
74.56 (73.73 – 75.40)*

67.96 (66.74 – 69.18) ref
75.68 (71.47 – 79.88)*

–
–
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Study Variables
Hispanic
Other
County employment: uppermiddle
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
County employment: lowermiddle
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
County employment: lowest
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Contextual-level factors:
Metro/nonmetro residence c
Metro
Nonmetro
County education d
Highest
Upper-middle
Lower-middle
Lowest
County employment e
Highest
Upper-middle
Lower-middle
Lowest
County poverty f
Highest
Upper-middle
Lower-middle
Lowest
Random effect
County variance

Advanced Stage Diagnosis
% b (95%CI)
67.77 (63.74 – 71.80)
70.54 (67.42 – 73.65)

Receipt of Surgery
% b (95%CI)
–
–

69.14 (67.93 – 70.34) ref
68.65 (64.16 – 73.13)
69.46 (66.59 – 72.33)
68.54 (65.25 – 71.83)

–
–
–
–

68.38 (67.03 – 69.73) ref
69.94 (66.70 – 73.18)
67.91 (65.52 – 70.31)
67.74 (64.73 – 70.76)

–
–
–
–

68.15 (66.77 – 69.53) ref
70.27 (67.43 – 73.10)
71.43 (68.79 – 74.07)*
69.80 (65.26 – 74.34)

–
–
–
–

68.84 (68.31 – 69.37) ref
68.11 (66.45 – 69.76)

82.52 (82.02 – 83.01) ref
82.22 (81.10 – 83.33)

68.96 (67.83 – 70.08) ref
68.84 (67.76 – 69.91)
68.74 (67.70 – 69.77)
68.52 (67.27 – 69.77)

83.21 (82.35 – 84.08)
82.57 (81.73 – 83.42)
82.12 (81.22 – 83.03)
82.03 (80.91 – 83.14)

68.80 (67.68 – 69.92) ref
69.09 (68.01 – 70.16)
68.39 (67.28 – 69.50)
68.92 (67.73 – 70.11)

82.59 (81.74 – 83.45) ref
83.04 (82.15 – 83.92)
82.59 (81.49 – 83.69)
81.78 (80.84 – 82.72)

67.92 (66.75 – 69.10) ref
68.23 (67.16 – 69.31)
69.44 (68.34 – 70.54)
69.53 (68.20 – 70.87)

82.78 (81.81 – 83.75) ref
81.96 (81.01 – 82.92)
82.90 (81.96 – 83.85)
82.23 (81.25 – 83.21)

<0.0001

0.0382*

Notes: a Adjusted for all the variables listed in the table, year of diagnosis, interactions between race/ethnicity and
county employment, and county random effects. b Average adjusted predicted probabilities. c Metro vs. nonmetro

77
categories are based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research
Service, U.S. Department of Agriculture. d Sorted by percentage of a county population with less than 9th grade
education in ascending order, and categorized into quartiles. e Sorted by percentage of persons aged 16 and over who
are unemployed in a county in ascending order, and categorized into quartiles. f Sorted by percentage of persons in a
county whose incomes are below the 100% federal poverty level threshold in ascending order, and categorized into
quartiles.
CI, confidence interval. ref reference group. * p<0.05
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Appendix B: Table 3.1
Models with Insurance Status: Factors Contributing to Disparities in Advanced Stage Diagnosis and Receipt of Surgery, by
Race/Ethnicity a
Study Variables

Age at diagnosis
18-45
46-55
56-65
66-75
>=76
Marital status
Not married
Married
Insurance
Uninsured
Insured

Advanced Stage Diagnosis
% b (95%CI)
Non–Hispanic
Non–Hispanic
Hispanic
White
Black
(n=3.460)
(n=19.328)
(n=2,278)

Non–Hispanic
White
(n=19.328)

Receipt of Surgery
% b (95%CI)
Non–Hispanic
Black
(n=2,278)

Hispanic
(n=3.460)

54.71 ref
(52.62 – 56.79)
64.90*
(63.48 – 66.32)
70.43*
(69.25 – 71.60)
74.20*
(72.93 – 75.47)
78.87*
(77.57 – 80.16)

56.99 ref
(51.95 – 62.03)
67.98*
(63.74 – 72.21)
76.08*
(72.62 – 79.54)
78.40*
(74.71 – 82.09)
83.30*
(79.38 – 87.21)

51.78 ref
(48.63 – 54.93)
63.74*
(60.66 – 66.82)
70.21*
(67.09 – 73.34)
74.92*
(71.31 – 78.54)
75.49*
(71.23 – 79.76)

95.40 ref
(94.34 – 96.46)
91.09 *
(90.09 – 92.10)
86.72*
(85.87 – 87.57)
82.94*
(82.05 – 83.84)
72.37*
(71.32 – 73.43)

87.66 ref
(84.10 – 91.22)
75.69*
(72.23 – 79.15)
71.97*
(68.97 – 74.97)
64.29*
(61.02 – 67.57)
54.86*
(50.76 – 58.96)

94.17 ref
(92.50 – 95.84)
86.63*
(84.50 – 88.75)
84.54*
(82.45 – 86.64)
79.14*
(76.55 – 81.73)
68.08*
(64.38 – 71.78)

70.23 ref
(69.34 –71.11)
69.74
(68.94 – 70.54)

73.30 ref
(71.24 – 75.35)
71.4 0
(68.15 – 74.64)

65.51 ref
(63.48 – 67.54)
64.18
(62.08 – 66.28)

81.48 ref
(80.91 – 82.05)
84.87*
(84.31 – 85.42)

68.65 ref
(66.93 – 70.36)
73.67*
(71.05 – 76.28)

82.34 ref
(81.06 – 83.63)
85.46*
(84.07 – 86.86)

70.17 ref
(67.02 –73.32)
69.95
(69.36 – 70.55)

69.26ref
(62.77 – 75.76)
73.04
(71.24 – 74.84)

67.78 ref
(63.3 – 72.26)
64.53
(63.00 – 66.06)

77.54 ref
(74.94 – 80.15)
83.28*
(82.89 – 83.67)

70.37 ref
(64.66 – 76.08)
70.10
(68.64 – 71.56)

80.39 ref
(77.03 – 83.75)
84.02*
(83.06 – 84.98)
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Study Variables

Stage
Non-advanced
Advanced
Grade
Well differentiated
Moderately
differentiated
Poorly
differentiated
Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell
Other or
unspecified

Advanced Stage Diagnosis
% b (95%CI)

Receipt of Surgery
% b (95%CI)

93.44 ref
(92.65 – 94.23)
80.52
(80.01 – 81.02)*

88.88 ref
(86.06 – 91.71)
64.78
(62.93 – 66.63)*

96.23 ref
(94.88 – 97.58)
79.27
(77.94 – 80.61)*

36.80 ref
(30.39 – 43.21)
59.70*
(55.13 – 64.27)
68.52*
(65.72 – 71.33)
69.85*
(65.47 – 74.23)
68.01*
(65.45 – 70.58)

93.52 ref
(90.88 – 96.15)
92.59
(91.08 – 94.09)
92.42
(91.76 – 93.08)
95.79
(94.98 – 96.60)
68.14*
(67.10 – 69.19)

90.74 ref
(82.19 – 99.29)
92.12
(87.03 – 97.21)
86.82
(84.21 – 89.43)
86.82
(82.42 – 91.23)
52.41*
(49.58 – 55.24)

98.23 ref
(94.96 – 101.49)
94.92
(91.93 – 97.9)
92.25*
(90.65 – 93.85)
93.26
(91.01 – 95.51)
71.39*
(69.19 – 73.58)

79.55 ref
(77.35 – 81.76)
43.12*
(36.13 – 50.10)
40.68*
(35.07 – 46.29)
36.09*
(28.95 – 43.23)
63.17*
(60.40 – 65.95)

88.41 ref
(87.83 – 89.00)
86.61*
(84.14 – 89.07)
93.02*
(90.74 – 95.3)
94.62*
(92.67 – 96.57)
75.21*
(74.38 – 76.05)

78.85 ref
(76.49 – 81.20)
68.82*
(60.47 – 77.17)
83.24
(72.71 – 93.78)
83.44
(71.54 – 95.34)
61.98*
(59.54 – 64.42)

89.42 ref
(88.03 – 90.81)
83.13*
(77.92 – 88.34)
94.43*
(90.13 – 98.72)
90.81
(85.96 – 95.66)
76.20*
(74.31 – 78.09)

–

–

–

–

–

–

42.45 ref
(39.31 – 45.59)
58.62*
(56.64 – 60.60)
73.21*
(72.13 – 74.30)
72.69 *
(71.11 – 74.27)
75.41*
(74.32 – 76.50)

39.32 ref
(30.31 – 48.33)
61.85*
(54.97 – 68.74)
74.58*
(71.08 – 78.08)
79.31*
(73.64 – 84.98)
77.15*
(74.48 – 79.82)

82.00 ref
(81.19 – 82.82)
48.46 *
(44.92 – 51.99)
41.87*
(39.18 – 44.56)
37.54*
(34.57 – 40.50)
68.15*
(66.89 – 69.41)

82.37 ref
(79.81 – 84.92)
56.88*
(47.7 – 66.06)
46.34 *
(36.54 – 56.14)
58.20*
(46.07 – 70.32)
70.21*
(67.26 – 73.15)
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Study Variables

Contextual-level
factors:
Metro/nonmetro
Residence c
Metro
Nonmetro
County Education d
Highest
Upper-middle
Lower-middle
Lowest
County Employment e
Highest
Upper-middle
Lower-middle
Lowest

Advanced Stage Diagnosis
% b (95%CI)

Receipt of Surgery
% b (95%CI)

70.10 ref
(69.47 – 70.73)
69.03
(67.28 – 70.78)

72.94 ref
(71.11 – 74.78)
70.6 0
(63.77 – 77.44)

64.76 ref
(63.28 – 66.23)
67.63
(59.82 – 75.43)

83.12 ref
(82.70 – 83.54)
83.19
(82.07 – 84.31)

70.62 ref
(69.13 – 72.11)
64.71
(58.94 – 70.49)

83.82 ref
(82.88 – 84.76)
80.64
(75.20 – 86.09)

70.45 ref
(69.29 – 71.61)
70.21
(69.03 – 71.40)
69.92
(68.67 – 71.16)
68.91
(67.35 – 70.46)

71.21 ref
(66.7 – 75.71)
72.17
(68.69 – 75.65)
73.80
(70.23 – 77.37)
73.75
(69.18 – 78.31)

62.72 ref
(56.33 – 69.10)
63.26
(58.68 – 67.84)
63.82
(60.51 – 67.13)
66.12
(63.55 – 68.68)

83.60 ref
(82.83 – 84.37)
83.11
(82.33 – 83.88)
82.74
(81.91 – 83.57)
82.90
(81.89 – 83.92)

69.54 ref
(65.85 – 73.23)
71.13
(68.37 – 73.90)
71.70
(68.69 – 74.71)
67.10
(63.28 – 70.91)

86.94 ref
(83.25 – 90.63)
85.01
(82.24 – 87.79)
83.37
(81.16 – 85.59)
83.11
(81.44 – 84.77)

69.32 ref
(68.14 – 70.49)
70.68
(69.50 – 71.87)
70.16
(68.82 – 71.50)
69.73
(68.35 – 71.12)

78.36 ref
(74.1 – 82.61)
71.05*
(66.22 – 75.88)
71.34*
(67.28 – 75.4)
72.22*
(68.82 – 75.62)

64.56 ref
(59.74 – 69.38)
66.78
(63.17 – 70.40)
62.33
(59.47 – 65.19)
66.91
(63.64 – 70.18)

83.34 ref
(82.56 – 84.12)
83.38
(82.58 – 84.17)
83.40
(82.51 – 84.30)
82.39
(81.49 – 83.30)

72.28 ref
(68.47 – 76.10)
72.06
(68.25 – 75.88)
71.62
(68.51 – 74.73)
67.41
(64.51 – 70.30)

84.85 ref
(81.75 – 87.95)
86.43
(84.10 – 88.76)
83.72
(81.92 – 85.52)
81.12
(78.91 – 83.33)
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Study Variables
County Poverty f
Highest
Upper-middle
Lower-middle
Lowest

Advanced Stage Diagnosis
% b (95%CI)
69.04 ref
(67.75 – 70.33)
69.69
(68.51 – 70.87)
70.41
(69.07 – 71.74)
71.03
(69.51 – 72.54)

71.58 ref
(66.13 – 77.04)
70.92
(66.02 – 75.82)
73.26
(69.53 – 77.00)
73.42
(70.06 – 76.79)

64.37 ref
(59.65 – 69.09)
62.15
(57.88 – 66.41)
66.14
(63.54 – 68.73)
65.20
(60.75 – 69.65)

Receipt of Surgery
% b (95%CI)
83.41 ref
(82.55 – 84.26)
82.75
(81.96 – 83.55)
83.67
(82.80 – 84.54)
82.67
(81.67 – 83.67)

67.83 ref
(63.25 – 72.41)
67.84
(63.83 – 71.85)
71.55
(68.6 – 74.50)
70.60
(67.77 – 73.43)

82.06 ref
(78.63 – 85.48)
82.01
(78.91 – 85.12)
84.1
(82.52 – 85.67)
85.22
(82.70 – 87.73)

Notes: a Adjusted for all the variables listed and year of diagnosis. b Average adjusted predicted probabilities. c Metro vs. nonmetro categories are based on the RuralUrban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. Department of Agriculture. d Sorted by percentage of a county
population with less than 9th grade education in ascending order, and categorized into quartiles. e Sorted by percentage of persons aged 16 and over who are
unemployed in a county in ascending order, and categorized into quartiles. f Sorted by percentage of persons in a county whose incomes are below the 100% federal
poverty level threshold in ascending order, and categorized into quartiles.
CI, confidence interval. ref reference group. * p<0.05
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Appendix C: Table 4.1
Model with Insurance Status: Adjusted Hazard Ratios for Ovarian Cancer-Cause Specific
Mortality a
Study Variables

Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Age at diagnosis
18-45
46-55
56-65
66-75
>=76
Marital status
Not married
Married
Insurance
Uninsured
Insured
Stage
Non-advanced
Advanced
Surgery
No
Yes
Grade
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell
Other or unspecified

Ovarian Cancer-Cause
Specific Mortality
(N=27,539)
HR (95%CI)
Ref.
0.79 (0.56 – 1.10)
0.80 (0.60 – 1.07)
0.93 (0.61 – 1.40)
Ref.
1.29 (1.17 – 1.43)*
1.46 (1.33 – 1.61)*
1.78 (1.62 – 1.96)*
2.56 (2.32 – 2.82)*
Ref.
0.86 (0.82 – 0.90)*
Ref.
0.80 (0.69 – 0.94)*
Ref.
3.93 (3.63 – 4.26)*
Ref.
0.29 (0.27 – 0.31)*
Ref.
2.11 (1.73 – 2.56)*
2.75 (2.28 – 3.31)*
2.60 (2.14 – 3.15)*
2.51 (2.08 – 3.03)*
Ref.
1.77 (1.56 – 2.00)*
0.75 (0.66 – 0.86)*
1.42 (1.26 – 1.59)*
1.35 (1.28 – 1.42)*
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Study Variables

Interaction:
Race/ethnicity * insurance
NHW * uninsured
NHB * insured
Hispanic * insured
Other * insured
Contextual-level factors:
Metro/nonmetro residence b
Metro
Nonmetro
County education c
Highest
Upper-middle
Lower-middle
Lowest
County employment d
Highest
Upper-middle
Lower-middle
Lowest
County poverty e
Highest
Upper-middle
Lower-middle
Lowest
Random effect
County variance

Ovarian Cancer-Cause
Specific Mortality
(N=27,539)
HR (95%CI)
Ref.
1.56 (1.11 – 2.20)*
1.29 (0.96 – 1.73)
1.08 (0.71 – 1.65)

Ref.
1.13 (1.05 – 1.21)*
Ref.
0.96 (0.90 – 1.03)
0.98 (0.91 – 1.05)
1.00 (0.92 – 1.08)
Ref.
0.93 (0.87 – 0.99)*
0.96 (0.89 – 1.03)
1.01 (0.94 – 1.09)
Ref.
1.05 (0.98 – 1.13)
1.02 (0.94 – 1.10)
1.05 (0.96 – 1.14)
0.0015

Notes: a Adjusted for all the variables listed in the table, year of diagnosis, interaction between race/ethnicity and
insurance status, and county random effect. b Metro vs. nonmetro categories are based on the Rural-Urban
Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. Department of
Agriculture. c Sorted by percentage of a county population with less than 9 th grade education in ascending order, and
categorized into quartiles. d Sorted by percentage of persons aged 16 and over who are unemployed in a county in
ascending order, and categorized into quartiles. e Sorted by percentage of persons in a county whose incomes are
below the 100% federal poverty level threshold in ascending order, and categorized into quartiles.
HR, hazard ratio. CI, confidence interval. Ref., reference group. * p<0.05
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Appendix D: Table 5.1
Models with Insurance Status: Factors Contributing to Disparities in Ovarian Cancer-Cause
Specific Mortality, by Race/Ethnicity a
Study Variables

Age at diagnosis
18-45
46-55
56-65
66-75
>=76
Marital status
Not married
Married
Insurance
Uninsured
Insured
Stage
Non-advanced
Advanced
Surgery
No
Yes
Grade
Well differentiated
Moderately
differentiated
Poorly
differentiated
Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell
Other or
unspecified
Contextual-Level
Factors:

Ovarian Cancer-Cause Specific Mortality
HR (95%CI)
Non–Hispanic
Non–Hispanic
Hispanic
White
Black
(n=3,460)
(n=19.328)
(n=2,278)
Ref.
1.34 (1.17 – 1.53)*
1.53 (1.35 – 1.74)*
1.88 (1.66 – 2.14)*
2.75 (2.42 – 3.13)*

Ref.
1.18 (0.90 – 1.55)
1.24 (0.96 – 1.62)
1.31 (1.01 – 1.71)*
1.86 (1.42 – 2.45)*

Ref.
1.30 (1.03 – 1.64)*
1.49 (1.19 – 1.87)*
1.88 (1.48 – 2.39)*
2.55 (1.97 – 3.29)

Ref.
0.84 (0.80 – 0.89)*

Ref.
0.88 (0.75 – 1.02)

Ref.
0.93 (0.81 – 1.07)

Ref.
0.79 (0.68 – 0.93)*

Ref.
1.36 (0.99 – 1.86)

Ref.
1.03 (0.8 – 1.34)

Ref.
3.93 (3.57 – 4.33)*

Ref.
2.94 (2.32 – 3.74)*

Ref.
4.95 (3.88 – 6.33)*

Ref.
0.30 (0.28 – 0.33)*

Ref.
0.29 (0.24 – 0.35)*

Ref.
0.26 (0.21 – 0.31)*

Ref.
2.05 (1.62 – 2.59)*

Ref.
2.15 (1.17 – 3.95)*

Ref.
2.04 (1.19 – 3.49)*

2.67 (2.14 – 3.34)*

3.11 (1.79 – 5.41)*

2.82 (1.69 – 4.68)*

2.48 (1.97 – 3.12)*
2.57 (2.05 – 3.22)*

3.26 (1.81 – 5.86)*
2.43 (1.39 – 4.23)*

2.82 (1.66 – 4.78)*
2.09 (1.25 – 3.50)*

Ref.
1.69 (1.45 – 1.97)*
0.75 (0.64 – 0.88)*
1.31 (1.13 – 1.51)*
1.30 (1.22 – 1.38)*

Ref.
2.12 (1.53 – 2.95)*
0.57 (0.34 – 0.96)*
1.73 (1.09 – 2.75)*
1.43 (1.22 – 1.68 *

Ref.
2.31 (1.66 – 3.20)*
1.08 (0.77 – 1.50)
2.43 (1.72 – 3.43)*
1.65 (1.41 – 1.93)*
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Study Variables

Metro/nonmetro
residence b
Metro
Nonmetro
County education c
Highest
Upper-middle
Lower-middle
Lowest
County employment d
Highest
Upper-middle
Lower-middle
Lowest
County poverty e
Highest
Upper-middle
Lower-middle
Lowest

Ovarian Cancer-Cause Specific Mortality
HR (95%CI)
Non–Hispanic
Non–Hispanic
Hispanic
White
Black
(n=3,460)
(n=19.328)
(n=2,278)
Ref.
1.14 (1.05 – 1.23)*

Ref.
1.07 (0.82 – 1.39)

Ref.
1.20 (0.87 – 1.66)

Ref.
0.95 (0.88 – 1.02)
0.98 (0.91 – 1.06)
0.95 (0.87 – 1.04)

Ref.
1.02 (0.82 – 1.28)
0.96 (0.75 – 1.21)
1.18 (0.93 – 1.49)

Ref.
1.10 (0.79 – 1.52)
1.12 (0.83 – 1.52)
1.17 (0.84 – 1.62)

Ref.
0.93 (0.87 – 1.00)
0.99 (0.92 – 1.07)
0.98 (0.91 – 1.07)

Ref.
0.85 (0.66 – 1.09)
0.92 (0.73 – 1.15)
1.14 (0.91 – 1.43)

Ref.
0.80 (0.62 – 1.03)
0.73 (0.56 – 0.96)*
0.84 (0.65 – 1.08)

Ref.
1.06 (0.99 – 1.14)
1.03 (0.95 – 1.12)
1.12 (1.02 – 1.22)*

Ref.
0.97 (0.75 – 1.26)
0.89 (0.69 – 1.15)
0.76 (0.59 – 0.99)*

Ref.
0.80 (0.62 – 1.03)
0.73 (0.56 – 0.96)
0.84 (0.65 – 1.08)

Notes: a Adjusted for all the variables listed in the table and year of diagnosis. b Metro vs. nonmetro categories are
based on the Rural-Urban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S.
Department of Agriculture. c Sorted by percentage of a county population with less than 9 th grade education in
ascending order, and categorized into quartiles. d Sorted by percentage of persons aged 16 and over who are
unemployed in a county in ascending order, and categorized into quartiles. e Sorted by percentage of persons in a
county whose incomes are below the 100% federal poverty level threshold in ascending order, and categorized into
quartiles.
HR, hazard ratio. CI, confidence interval. Ref., reference group. * p<0.05
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Appendix E: Table 6
Racial/ethnic Disparities in Advanced Stage Diagnosis, Receipt of Surgery and Survival: Trend over time, 2001-2012
Year

Late Stage Diagnosis (OR)
NHW vs. NHW vs.
NHB vs.
NHB
Hispanic
Hispanic
1.06
0.89
0.75
2001
1.24
1.17
0.79
2002
1.02
1.15
1.17
2003
0.99
1.07
1.14
2004
0.96
1.06
1.03
2005
1.05
0.68
0.60
2006
0.98
1.19
0.98
2007
1.27
1.02
0.73
2008
1.10
1.17
0.89
2009
1.02
1.08
1.07
2010
1.01
0.76
0.78
2011
1.52
1.22
0.71
2012
*
AAPC (%)
1.24
0.00
-1.28
P value
0.30
1.00
0.50
*
OR, odds, ratio. Average Annual Percent Change

Receipt of Surgery (OR)
NHW vs. NHW vs.
NHB vs.
NHB
Hispanic
Hispanic
0.39
1.23
3.91
0.46
0.75
1.47
0.44
0.61
1.40
0.50
0.83
1.86
0.61
0.93
1.73
0.33
1.14
3.63
0.33
0.77
2.24
0.53
0.62
1.36
0.56
0.67
1.19
0.53
0.82
1.52
0.64
0.82
1.54
0.56
0.84
1.56
2.95
-1.09
-3.86
0.10
0.55
0.20

Ovarian Cancer Mortality (HR)
NHW vs. NHW vs.
NHB vs.
NHB
Hispanic
Hispanic
1.52
1.02
0.72
1.03
0.84
0.73
1.47
0.98
0.68
1.24
0.94
0.72
1.28
0.98
0.66
1.17
1.14
0.95
1.21
1.00
0.72
1.17
0.94
0.76
1.22
1.22
1.01
1.21
1.16
0.94
1.18
0.82
0.6
1.02
0.99
0.73
-1.48
1.12
1.57
0.17
0.32
0.29
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Appendix F: Table 2.2
Adjusted Odds Ratio of Advanced Stage Diagnosis and Receipt of Surgery a
Study Variables

Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
Age at diagnosis
18-45
46-55
56-65
66-75
>=76
Marital status
Not married
Married
Stage
Non-advanced
Advanced
Grade
Well differentiated
Moderately
differentiated
Poorly differentiated
Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell
Other or unspecified
Interaction:
race/ethnicity*county
employment
NHW * highest
NHB * upper middle
NHB * lower middle

Advanced Stage Diagnosis
(N=54,580)
OR (95%CI)

Receipt of Surgery
(N=54,580)
OR (95%CI)

Ref.
1.47 (1.18 – 1.84)*
0.90 (0.75 – 1.09)
1.12 (0.95 – 1.31)

Ref.
0.48 (0.43 – 0.54)*
0.82 (0.74 – 0.92)*
0.82 (0.71 – 0.94)*

Ref.
1.68 (1.57 – 1.80)*
2.38 (2.23 – 2.55)*
3.04 (2.83 – 3.27)*
3.93 (3.63 – 4.25)*

Ref.
0.41 (0.35 – 0.48)*
0.25 (0.21 – 0.29)*
0.16 (0.14 – 0.18)*
0.06 (0.05 – 0.07)*

Ref.
0.95 (0.90 – 0.99)*

Ref.
1.53 (1.43 – 1.64)*

Ref.
–

Ref.
0.10 (0.09 – 0.11)

Ref.
2.28 (2.07 – 2.51)*

Ref.
1.13 (0.84 – 1.51)

4.95 (4.52 – 5.42)*
4.67 (4.20 – 5.19)*
4.66 (4.25 – 5.11)*

1.00 (0.77 – 1.32)
1.56 (1.16 – 2.09)*
0.10 (0.07 – 0.12)*

Ref.
0.19 (0.17 – 0.21)*
0.15 (0.14 – 0.16)*
0.11 (0.10 – 0.12)*
0.45 (0.42 – 0.47)*

Ref.
0.49 (0.42 – 0.58)*
1.54 (1.21 – 1.96)*
1.81 (1.42 – 2.30)*
0.18 (0.16 – 0.19)*

Ref.
0.76 (0.56 – 1.01)
0.71 (0.54 – 0.93)*

–
–
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NHB * lowest
Hispanic * upper middle
Hispanic * lower middle
Hispanic * lowest
Other * upper middle
Other * lower middle
Other * lowest
Contextual-level
factors:
Metro/nonmetro residence b
Metro
Nonmetro
County education c
Highest
Upper-middle
Lower-middle
Lowest
County employment d
Highest
Upper-middle
Lower-middle
Lowest
County poverty e
Highest
Upper-middle
Lower-middle
Lowest
Random effect
County variance

0.71 (0.54 – 0.92)*
1.12 (0.88 – 1.42)
1.14 (0.92 – 1.42)
1.17 (0.93 – 1.49)
0.83 (0.66 – 1.04)
0.71 (0.58 – 0.87)*
0.88 (0.67 – 1.17)

–
–
–
–
–
–
–

Ref.
0.98 (0.90 – 1.05)

Ref.
0.94 (0.83 – 1.05)

Ref.
0.94 (0.87 – 1.01)
0.97 (0.89 – 1.05)
0.93 (0.84 – 1.01)

Ref.
1.04 (0.91 – 1.18)
0.99 (0.86 – 1.14)
1.03 (0.89 – 1.19)

Ref.
1.06 (0.98 – 1.15)
1.07 (0.99 – 1.17)
1.02 (0.93 – 1.13)

Ref.
0.99 (0.88 – 1.11)
1.00 (0.88 – 1.13)
0.89 (0.78 – 1.03)

Ref.
1.04 (0.97 – 1.13)
1.13 (1.03 – 1.24)*
1.16 (1.05 – 1.28)*

Ref.
0.90 (0.79 – 1.03)
0.91 (0.78 – 1.06)
0.89 (0.76 – 1.05)

0.007

0.0451*

Notes: a Adjusted for all the variables listed in the table, year of diagnosis, interaction between race/ethnicity and
county employment, and county random effects. b Metro vs. nonmetro categories are based on the Rural-Urban
Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. Department of
Agriculture. c Sorted by percentage of a county population with less than 9 th grade education in ascending order, and
categorized into quartiles. d Sorted by percentage of persons aged 16 and over who are unemployed in a county in
ascending order, and categorized into quartiles. e Sorted by percentage of persons in a county whose incomes are
below the 100% federal poverty level threshold in ascending order, and categorized into quartiles.
OR, odds ratio. CI, confidence interval. Ref. reference group. * p<0.05
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Appendix G: Table 3.2
Factors Contributing to Disparities in Advanced Stage Diagnosis and Receipt of Surgery, by Race/Ethnicity (Odds Ratio) a
Study Variables

Age at diagnosis
18-45
46-55
56-65
66-75
>=76
Marital status
Not married
Married
Stage
Non-advanced
Advanced
Grade
Well
differentiated
Moderately
differentiated
Poorly
differentiated
Undifferentiated
Unknown
Histology
Serous
Mucinous
Endometrioid
Clear cell

Advanced Stage Diagnosis
OR(95%CI)
Non–Hispanic
Non–Hispanic
White
Black
(n=39,726)
(n=4,295)

Hispanic
(n=6,256)

Non–Hispanic
White
(n=39,726)

Receipt of Surgery
OR (95%CI)
Non–Hispanic
Black
(n=4,295)

Hispanic
(n=6,256)

Ref.
1.71 (1.56 – 1.86)*
2.38 (2.18 – 2.59)*
3.03 (2.77 – 3.32)*
3.95 (3.60 – 4.34)*

Ref.
1.67 (1.33 – 2.10)*
2.43 (1.93 – 3.05)*
2.88 (2.25 – 3.68)*
4.03 (3.05 – 5.31)*

Ref.
1.74 (1.48 – 2.06)*
2.63 (2.19 – 3.15)*
3.28 (2.68 – 4.02)*
3.70 (2.92 – 4.68)*

Ref.
0.45 (0.36 – 0.57)*
0.25 (0.21 – 0.31)*
0.16 (0.13 – 0.20)*
0.06 (0.05 – 0.07)*

Ref.
0.48 (0.33 – 0.68)*
0.28 (0.20 – 0.39)*
0.18 (0.13 – 0.25)*
0.09 (0.06 – 0.13)*

Ref
0.27 (0.19 – 0.38)*
0.24 (0.17 – 0.33)*
0.14 (0.10 – 0.19)*
0.05 (0.03 – 0.07)*

Ref.
0.94 (0.89 – 0.99)*

Ref.
0.88 (0.74 – 1.04)

Ref.
0.93 (0.82 – 1.06)

Ref.
1.59 (1.47 – 1.72)*

Ref.
1.51 (1.22 – 1.86)*

Ref
1.31 (1.08 – 1.60)*

Ref.
–

Ref.
–

Ref.
–

Ref.
0.11 (0.09 – 0.12)*

Ref.
0.11 (0.08 – 0.14)*

Ref
0.06 (0.04 – 0.08)*

Ref.

Ref.

Ref.

Ref.

Ref.

Ref

2.18 (1.95 – 2.45)*

2.80 (1.95 – 4.02)*

2.74 (2.09 – 3.60)*

1.30 (0.93 – 1.81)

0.51 (0.17 – 1.53)

0.75 (0.27 – 2.10)

4.78 (4.29 – 5.33)*

5.38 (3.83 – 7.55)*

5.06 (3.91 – 6.53)*

1.25 (0.92 – 1.69)

0.35 (0.12 – 0.99)*

0.63 (0.24 – 1.64)

4.48 (3.96 – 5.07)*
4.66 (4.17 – 5.20)*

5.64 (3.72 – 8.53)*
5.42 (3.89 – 7.55)*

5.17 (3.79 – 7.03)*
4.38 (3.40 – 5.64)*

2.14 (1.53 – 2.99)*
0.11 (0.08 – 0.15)*

0.40 (0.13 – 1.20)
0.04 (0.01 – 0.11)*

0.67 (0.24 – 1.83)
0.06 (0.02 – 0.16)*

Ref.
0.18 (0.16 – 0.20)*
0.14 (0.13 – 0.15)*
0.11 (0.10 – 0.12)*

Ref.
0.26 (0.19 – 0.36)*
0.16 (0.12 – 0.22)*
0.17 (0.11 – 0.26)*

Ref.
0.21 (0.17 – 0.27)*
0.17 (0.14 – 0.21)*
0.13 (0.10 – 0.17)*

Ref.
0.49 (0.40 – 0.60)*
1.45 (1.09 – 1.92)*
2.05 (1.51 – 2.78)*

Ref.
0.47 (0.30 – 0.75)*
1.26 (0.65 – 2.44)
0.90 (0.42 – 1.95)

Ref
0.55 (0.35 – 0.88)*
2.32 (1.03 – 5.25)*
1.19 (0.64 – 2.21)
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Study Variables

Other or
unspecified
Contextual-Level
Factors:
Metro/nonmetro
Residence b
Metro
Nonmetro
County
Education c
Highest
Upper-middle
Lower-middle
Lowest
County
Employment d
Highest
Upper-middle
Lower-middle
Lowest
County Poverty e
Highest
Upper-middle
Lower-middle
Lowest
Random Effect
County Variance
:a

Advanced Stage Diagnosis
OR(95%CI)
Non–Hispanic
Non–Hispanic
Hispanic
White
Black
(n=6,256)
(n=39,726)
(n=4,295)
0.47 (0.44 – 0.50)*
0.42 (0.34 – 0.51)* 0.39 (0.34 – 0.46)*

0.17 (0.16 – 0.19)*

0.22 (0.18 – 0.27)*

Ref.
0.98 (0.91 – 1.07)

Ref.
0.78 (0.58 – 1.06)

Ref.
0.95 (0.67 – 1.35)

Ref.
1.01 (0.89 – 1.16)

Ref.
0.86 (0.60 – 1.23)

Ref.
0.94 (0.87 – 1.01)
0.95 (0.86 – 1.04)
0.92 (0.83 – 1.02)

Ref.
1.02 (0.78 – 1.33)
1.23 (0.92 – 1.64)
1.10 (0.81 – 1.48)

Ref.
0.88 (0.65 – 1.21)
1.02 (0.74 – 1.39)
0.97 (0.70 – 1.35)

Ref.
1.03 (0.90 – 1.19)
0.98 (0.84 – 1.15)
0.97 (0.81 – 1.16)

Ref.
1.27 (0.92 – 1.76)
1.15 (0.82 – 1.63)
0.95 (0.66 – 1.37)

Ref
0.85 (0.51 – 1.41)
0.84 (0.52 – 1.36)
0.97 (0.58 – 1.62)

Ref.
1.06 (0.98 – 1.15)
1.07 (0.99 – 1.17)
1.04 (0.95 – 1.15)

Ref.
0.77 (0.57 – 1.05)
0.71 (0.54 – 0.95)*
0.66 (0.49 – 0.90)*

Ref.
1.19 (0.92 – 1.54)
1.09 (0.82 – 1.45)
1.06 (0.78 – 1.42)

Ref.
1.01 (0.89 – 1.15)
0.95 (0.83 – 1.10)
0.98 (0.83 – 1.15)

Ref.
0.94 (0.66 – 1.35)
1.20 (0.86 – 1.68)
0.76 (0.53 – 1.09)

Ref
0.84 (0.56 – 1.26)
0.74 (0.48 – 1.15)
0.62 (0.39 – 0.97)*

Ref.
1.05 (0.97 – 1.14)
1.11 (1.01 – 1.22)*
1.14 (1.02 – 1.28)*

Ref.
1.04 (0.76 – 1.41)
1.09 (0.80 – 1.48)
1.25 (0.91 – 1.72)

Ref.
1.01 (0.77 – 1.32)
1.22 (0.90 – 1.63)
1.37 (0.99 – 1.91)

Ref.
0.90 (0.77 – 1.04)
0.91 (0.77 – 1.08)
0.80 (0.66 – 0.97)*

Ref.
0.86 (0.59 – 1.25)
1.04 (0.72 – 1.51)
1.14 (0.78 – 1.68)

Ref
1.03 (0.69 – 1.55)
0.88 (0.57 – 1.37)
1.00 (0.61 – 1.62)

0.0031

<0.0001

0.0248

0.0527*

<0.0001

Non–Hispanic
White
(n=39,726)

b

Receipt of Surgery
OR (95%CI)
Non–Hispanic
Black
(n=4,295)

Hispanic
(n=6,256)
0.17 (0.14 – 0.22)*

Ref
0.79 (0.47 – 1.34)

<0.0001

Notes Adjusted for all the variables listed in the table, year of diagnosis and county random effects. Metro vs. nonmetro categories are based on the RuralUrban Continuum Codes (RUCC Codes: 1-3 vs. 4-9) from the Economic Research Service, U.S. Department of Agriculture. c Sorted by percentage of a county
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population with less than 9th grade education in ascending order, and categorized into quartiles. d Sorted by percentage of persons aged 16 and over who are
unemployed in a county in ascending order, and categorized into quartiles. e Sorted by percentage of persons in a county whose incomes are below the 100%
federal poverty level threshold in ascending order, and categorized into quartiles.
OR, odds ratio. CI, confidence interval. Ref. reference group. * p<0.05

